Analogic (ALOG) Inactive 10-Q6 Jun 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Apr. 30, 2014	30-May-14
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Apr-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'ALOG	'
Entity Registrant Name	'ANALOGIC CORP	'
Entity Central Index Key	'0000006284	'
Current Fiscal Year End Date	'--07-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	12,374,972

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Apr. 30, 2014	Jul. 31, 2013
In Thousands, unless otherwise specified	Apr. 30, 2014	Jul. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$119,448	$113,033
Accounts receivable, net of allowance for doubtful accounts of $785 and $598 as of April 30, 2014 and July 31, 2013, respectively	94,841	113,150
Inventory	120,423	116,280
Refundable and deferred income taxes	14,688	7,803
Other current assets	10,211	10,147
Total current assets	359,611	360,413
Property, plant, and equipment, net	113,622	110,983
Intangible assets, net	59,450	55,525
Goodwill	56,955	50,073
Deferred income taxes	6,864	5,439
Other assets	5,940	5,351
Total assets	602,442	587,784
Current liabilities:	'	'
Accounts payable	40,290	32,138
Accrued employee compensation and benefits	16,114	22,264
Accrued warranty	6,177	6,501
Accrued restructuring charges	910	2,848
Deferred revenue	9,201	9,218
Customer advances	3,271	3,256
Accrued income taxes	'	4,091
Accrued expenses, other	3,454	5,293
Other current liabilities	6,037	5,285
Total current liabilities	85,454	90,894
Long-term liabilities:	'	'
Accrued income taxes	2,335	5,031
Other long-term liabilities	7,409	5,463
Total long-term liabilities	9,744	10,494
Guarantees and commitments (Notes 18 and 19)	'	'
Stockholders' equity:	'	'
Common stock, $0.05 par value; 30,000,000 shares authorized and 12,376,745 shares issued and outstanding as of April 30, 2014; 30,000,000 shares authorized and 12,235,416 shares issued and outstanding as of July 31, 2013	619	612
Capital in excess of par value	123,434	114,381
Retained earnings	372,416	362,255
Accumulated other comprehensive income	10,775	9,148
Total stockholders' equity	507,244	486,396
Total liabilities and stockholders' equity	$602,442	$587,784

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Apr. 30, 2014	Jul. 31, 2013
In Thousands, except Share data, unless otherwise specified	Apr. 30, 2014	Jul. 31, 2013
Accounts receivable, allowance for doubtful accounts	$785	$598
Common stock, par value	$0.05	$0.05
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	12,376,745	12,235,416
Common stock, shares outstanding	12,376,745	12,235,416

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Net revenue:	'	'	'	'
Product	$122,067	$121,188	$369,992	$366,498
Engineering	1,965	4,577	5,559	17,688
Total net revenue	124,032	125,765	375,551	384,186
Cost of sales:	'	'	'	'
Product	68,717	72,341	213,110	218,355
Engineering	1,961	4,284	5,067	16,206
Total cost of sales	70,678	76,625	218,177	234,561
Gross profit	53,354	49,140	157,374	149,625
Operating expenses:	'	'	'	'
Research and product development	16,915	16,127	55,795	46,324
Selling and marketing	14,338	13,540	43,603	37,062
General and administrative	12,764	12,265	40,624	37,793
Restructuring	-80	496	216	496
Total operating expenses	43,937	42,428	140,238	121,675
Income from operations	9,417	6,712	17,136	27,950
Other income (expenses), net	882	190	104	-1,118
Income before income taxes	10,299	6,902	17,240	26,832
Provision for (benefit from) income taxes	2,509	1,678	-6,089	7,418
Net income	$7,790	$5,224	$23,329	$19,414
Net income per common share:	'	'	'	'
Basic	$0.63	$0.42	$1.88	$1.58
Diluted	$0.62	$0.41	$1.84	$1.54
Weighted-average shares outstanding:	'	'	'	'
Basic	12,403	12,305	12,421	12,300
Diluted	12,647	12,620	12,679	12,584
Dividends declared and paid per share:	$0.10	$0.10	$0.30	$0.30

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Net income	$7,790	$5,224	$23,329	$19,414
Other comprehensive income (loss), net of tax:	'	'	'	'
Foreign currency translation adjustment	689	-1,378	1,495	4,343
Unrealized gains (losses) on foreign currency forward contracts, net of tax of $12 and $(38) for the three months ended April 30, 2014 and 2013, respectively, and $67 and $ (48) for the nine months ended April 30, 2014 and 2013, respectively	31	-69	132	-87
Total other comprehensive income (loss), net of tax	720	-1,447	1,627	4,256
Total comprehensive income	$8,510	$3,777	$24,956	$23,670

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Unrealized gains (losses) on foreign currency forward contracts, net of tax	$12	($38)	$67	($48)

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net income	$23,329	$19,414
Adjustments to reconcile net cash provided by operating activities:	'	'
(Benefit from) provision for deferred income taxes	-4,224	3,761
Depreciation and amortization	16,405	12,537
Loss on investment	484	'
Change in fair value of contingent consideration	183	-120
Share-based compensation expense	8,727	7,957
Excess tax benefit from share-based compensation	-3,449	-1,992
Write-down of inventory to net realizable value	3,111	2,560
Allowance for doubtful accounts	187	216
Other	'	689
Loss (gain) on sale of property, plant and equipment	27	-6
Net changes in operating assets and liabilities, exclusive of acquisition-related assets and liabilities:	'	'
Accounts receivable	18,558	15,885
Inventory	-6,978	-24,852
Refundable income taxes	-354	-4,226
Other current assets	753	-940
Accounts payable	7,774	-12,011
Accrued liabilities	-10,008	-4,286
Deferred revenue	-92	-2,031
Accrued income taxes	-9,741	-3,709
Other liabilities	-1,574	2,279
NET CASH FLOWS PROVIDED BY OPERATING ACTIVITIES	43,118	11,125
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Additions to property, plant, and equipment	-13,647	-19,885
Purchases of marketable securities	-624	'
Acquisition of business, net of cash acquired	-10,561	-79,273
Proceeds from the sale of property, plant, and equipment	140	83
NET CASH FLOWS USED IN INVESTING ACTIVITIES	-24,692	-99,075
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Issuance of stock pursuant to exercise of stock options, employee stock purchase plan, restricted stock plans, and non-employee director stock plan	4,454	5,086
Shares repurchased for taxes for vested employee restricted stock grants	-6,281	-4,498
Contingent consideration payment	'	-340
Excess tax benefit from share-based compensation	3,449	1,992
Borrowings of other credit facilities	'	2,230
Repayments of other credit facilities	'	-3,014
Repurchase of common stock	-10,579	-6,020
Dividends paid to shareholders	-3,727	-3,889
NET CASH FLOWS USED IN FINANCING ACTIVITIES	-12,684	-8,453
EFFECT OF EXCHANGE RATE CHANGES ON CASH	673	739
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	6,415	-95,664
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	113,033	187,011
CASH AND CASH EQUIVALENTS, END OF PERIOD	$119,448	$91,347

Business

Business	9 Months Ended
	Apr. 30, 2014
Business	'
	1. Business:
	Company
	Throughout this Quarterly Report on Form 10-Q, unless the context states otherwise, the words “we,” “us,” “our” and “Analogic” refer to Analogic Corporation and all of its subsidiaries taken as a whole, and “our board of directors” refers to the board of directors of Analogic Corporation.
	Description of Business
	Analogic (NASDAQ:ALOG) provides leading-edge healthcare and security technology solutions to advance the practice of medicine and save lives. We are recognized around the world for advanced imaging systems and technology that enable computed tomography, or CT, ultrasound, magnetic resonance imaging, or MRI, and digital mammography, as well as automated threat detection for aviation security. Our CT, MRI, digital mammography, and ultrasound transducer products are sold to original equipment manufacturers, or OEMs, providing state-of-the-art capability and enabling them to enter new markets and expand their existing market presence. Our state-of-the-art ultrasound systems are sold directly to clinical end users through our sales force under the BK Medical and Ultrasonix brands and are primarily used in procedure guidance markets such as urology, surgery, and point-of-care.
	We were incorporated in the Commonwealth of Massachusetts in November 1967 and our headquarters is based just north of Boston in Peabody, Massachusetts.
	Our business is strategically aligned into three segments: Medical Imaging, Ultrasound, and Security Technology. Our business segments are described below.

		•	Medical Imaging, which primarily includes systems and subsystems for CT and MRI medical imaging equipment as well as state-of-the-art, selenium-based detectors for screening of breast cancer and other diagnostic applications in mammography.

		•	Ultrasound, which includes ultrasound systems and transducers primarily in the urology, surgery (including robotic assisted surgery), anesthesia, and point-of-care markets.

		•	Security Technology, which includes advanced threat detecting CT systems utilizing our expertise in advanced imaging technology, primarily used in checked baggage screening at airports worldwide.
	Basis of Presentation
	Our unaudited condensed consolidated financial statements presented herein have been prepared pursuant to the rules of the United States Securities and Exchange Commission, or SEC, for quarterly reports on Form 10-Q. Preparing financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses.
	We report our financial condition and results of operations on a fiscal year basis ending on July 31st of each year. The three months ended April 30, 2014 and 2013 represent the third quarters of fiscal years 2014 and 2013, respectively.
	In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary for a fair statement of the results for all interim periods presented. These statements should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended July 31, 2013, or fiscal year 2013, included in our Annual Report on Form 10-K as filed with the SEC on September 30, 2013. The year end condensed balance sheet data were derived from audited financial statements, but do not include all disclosures required by generally accepted accounting principles in the United States, or U.S. GAAP.
	Consolidation
	The unaudited condensed consolidated financial statements presented herein include the accounts of us and our subsidiaries, all of which are wholly owned. Investments in companies in which our ownership interests range from 10% to 50% are accounted for using the equity method. Other investments are accounted for using the cost method.

	In determining whether we are the primary beneficiary of an entity and therefore required to consolidate, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We have not been required to consolidate the activity of any entity due to these considerations.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	9 Months Ended
Recent Accounting Pronouncements	Apr. 30, 2014
Recent Accounting Pronouncements	'
	2. Recent Accounting Pronouncements
	Recently adopted
	Testing indefinite-lived intangible assets for impairment
	In July 2012, the Financial Accounting Standards Board, or FASB, issued an update regarding testing indefinite-lived intangible assets for impairment. This update gives an entity the option first to assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, an entity concludes that it is more likely than not that the indefinite-lived intangible asset is not impaired, then the entity is not required to take further action. However, if an entity concludes otherwise, then it is required to determine the fair value of the indefinite-lived intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying amount. An entity also has the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. An entity will be able to resume performing the qualitative assessment in any subsequent period. The guidance is effective for the interim period ended October 31, 2013. We adopted this standard in the first quarter of the fiscal year ending July 31, 2014, or fiscal year 2014. The adoption of this standard did not have a material impact on our financial condition or results of operations.
	Presentation of unrecognized tax benefits
	In July 2013, the FASB issued an update, which is intended to eliminate the diversity that is in practice with regard to the financial statement presentation of unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective for our interim period ending January 31, 2014. We adopted this standard in the first quarter of fiscal year 2014 and presented this information in Note 15. Income Taxes. The adoption of this standard did not have a material impact on our financial condition or results of operations.
	Not yet effective
	Revenue from contracts with customers
	In May 2014, the FASB issued an update which provides guidance for revenue recognition. This update affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. This update will supersede existing revenue recognition guidance and most industry-specific guidance. This update also supersedes some cost guidance included in current revenue recognition guidance for construction-type and production-type contracts. The update’s core principle is that a company should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under today’s guidance. These estimates and judgments may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. This update will be effective for us in the first quarter of fiscal year 2018. Early adoption is not permitted. We are currently evaluating the impact of the adoption of this update on our consolidated financial statements.
	Foreign currency matters
	In March 2013, the FASB issued an update which amends guidance on foreign currency matters and consolidations to address diversity in practice related to the release of cumulative translation adjustments, or CTA, into earnings upon the occurrence of certain derecognition events. The update reflects a compromise between the CTA release guidance included within foreign currency matters and the loss of control concepts included within consolidation guidance. It precludes the release of CTA for derecognition events that occur within a foreign entity, unless such events represent a complete or substantially complete liquidation of the foreign entity. Derecognition events related to investments in a foreign entity result in the release of all CTA related to the derecognized foreign entity, even when a noncontrolling financial interest is retained. The update also amends guidance on business combinations and for transactions that result in a company obtaining control of a business in a step acquisition by increasing an investment in a foreign entity from one accounted for under the equity method to one accounted for as a consolidated investment. The update is effective for us beginning after August 1, 2014. This update should be applied prospectively and prior periods should not be adjusted. This update is not expected to have an impact on our financial condition or results of operations. Early adoption is permitted as of the beginning of an entity’s fiscal year.

Business_Combinations

Business Combinations	9 Months Ended
Business Combinations	Apr. 30, 2014
Business Combinations	'
	3. Business Combinations
	PocketSonics, Inc.
	In April 2010, we entered into an agreement with PocketSonics, Inc., or PocketSonics, a privately held ultrasound technology company based in Charlottesville, Virginia, which granted us an exclusive license to certain ultrasound technology owned or controlled by PocketSonics and a ten percent (10%) equity interest in PocketSonics. The equity investment was recorded as in-process research and development, or IPR&D, of $1.9 million. Since that time, we have collaborated with PocketSonics to develop patented ultrasound technology to enable the acceleration of high acuity guided procedures to lower cost point-of-care settings and other technical applications. On September 20, 2013, we acquired all of the remaining stock of PocketSonics. The purchase price includes base consideration of $11.1 million paid in cash at closing, fair value of contingent consideration of $1.9 million, and revaluation of the initial equity investment. We undertook this acquisition to further strengthen our competitive position in procedure guidance for point-of-care and other advanced guidance applications. The acquisition was funded from our existing cash on hand and has been accounted for as an acquisition of a business.
	The fair value of assets acquired and the liabilities assumed were based on estimates at the acquisition date. The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of September 20, 2013:


	(in millions)
	Cash		$	0.5
	Goodwill			6.9
	IPR&D			11.5

	Total assets acquired			18.9
	Accounts payable and accrued expenses			(0.3	)
	Deferred taxes			(4.1	)

	Total liabilities assumed			(4.4	)

	Total purchase price		$	14.5

	In determining the fair value, we considered, among other factors, market participants’ intentions to use the acquired assets and the historical and estimated future demand for PocketSonics products and services. We recognized an IPR&D asset of $11.5 million. The fair value of the asset was determined by a probability adjusted cash flow analysis. This intangible asset is currently an indefinite-lived asset and is subject to our annual impairment testing process. We expect to begin amortizing the IPR&D asset over the product life cycle once production of the product begins, which is expected within the next three to six months. We anticipate that the amortization period of the IPR&D asset will be approximately 10 years.
	In connection with this acquisition, we recorded a fair value contingent consideration obligation of $1.9 million, with potential of up to $3.0 million payable upon the achievement of certain milestones relating to the PocketSonics technology. The contingent earn-out payments payable to the sellers of PocketSonics would be met upon commercial launch and a volume sales target. The $1.9 million fair value was estimated through a valuation model that incorporates probability adjusted assumptions relating to the achievement of these milestones and the likelihood of us making payments. This fair value measurement is based upon significant inputs not observable in the market and therefore represents a Level 3 input measurement. Subsequent changes in the fair value of this obligation will be recognized as adjustments to contingent consideration liability and reflected within our condensed consolidated statement of operations within general and administrative operating expenses. During the three and nine months ended April 30, 2014, we incurred additional increases of $0.1 million and $0.2 million, respectively, in the fair value of our contingent consideration obligation. The total fair value of our contingent consideration obligation was $2.1 million as of April 30, 2014. For additional information related to the fair value of this obligation, please refer to Note 8. Fair Value Measurements.
	Upon the acquisition of PocketSonics, we recorded a goodwill asset of $6.9 million, representing the value of the opportunity of further strengthening our competitive position in procedure guidance for point-of-care and other advanced guidance applications. The goodwill will not be deductible for tax purposes.
	Upon the acquisition of PocketSonics, we recognized a loss of $0.5 million related to our 10% pre-acquisition equity interest, which is reflected as a component of other expense, net within our condensed consolidated statement of operations for the nine months ended April 30, 2014, respectively.

	During the nine months ended April 30, 2014, we incurred acquisition costs of $0.1 million which consisted primarily of legal and due diligence expenses that are included in our general and administrative expenses in our condensed consolidated statement of operations.
	Ultrasonix Medical Corporation, or Ultrasonix
	On March 1, 2013, we completed our acquisition of all of the outstanding equity securities of Ultrasonix Medical Corporation, a Nevada (U.S.) corporation, whose principal assets included customer lists and intangibles related solely to sales destined to the U.S. On March 2, 2013, we completed our acquisition of all of the outstanding equity securities of Ultrasonix Medical Corporation, a Canadian corporation, pursuant to a “plan of arrangement” under Canadian law. Ultrasonix is a supplier of advanced ultrasound systems for point-of-care and general imaging applications. We undertook the acquisition to accelerate our expansion into the point-of-care ultrasound market. The purchase price, net of cash acquired, was $79.9 million. The acquisition was funded from our existing cash on hand and has been accounted for as an acquisition of a business.
	The fair value of assets acquired and the liabilities assumed were based on estimates at the acquisition date. The fair value measurements of inventory, intangibles, property, plant and equipment and deferred revenue were based upon significant inputs not observable in the market and therefore represent fair value measurements based on Level 3 inputs. The purchase accounting was finalized during fiscal year 2014. The following table summarizes the purchase price allocation that includes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of March 2, 2013:


	(in millions)
	Cash						$	0.4
	Accounts receivable (A)							6.5
	Inventory (B)							9.4
	Prepaids and other assets							2.9
	Property, plant, and equipment							0.3
	Goodwill							48.2
	Intangible assets:
	Developed technology (weighted-average useful life of 10 years)			5.9
	Customer relationships (weighted-average useful life of 10.6 years)			18.5
	Tradename (estimate useful life of 2 years)			0.9

	Total intangible assets							25.3
	Other assets							0.1

	Total assets acquired							93.1
	Accounts payable and accrued expenses							(5.4	)
	Deferred revenue (B)							(0.8	)
	Accrued warranty							(1.1	)
	Debt							(0.8	)
	Deferred taxes							(4.7	)

	Total liabilities assumed							(12.8	)

	Total purchase price						$	80.3


	(A)	The gross amount due was $8.7 million, of which $2.2 million is expected to be uncollectible. We did not acquire any other class of receivables other than trade receivables as a result of the acquisition of Ultrasonix.
	(B)	The inventory fair value adjustment of $3.7 million associated with the acquisition was fully amortized as of October 31, 2013. The deferred revenue adjustment of $0.8 million associated with the acquisition will be amortized over 4.5 years. The inventory fair value and deferred revenue adjustments were recognized in product cost of sales and product revenue in our condensed consolidated statement of operations, respectively.
	During the three months and nine months ended April 30, 2014, we incurred acquisition related charges of approximately $1.9 million and $6.2 million, respectively, primarily related to intangible amortization expense of $5.7 million as well as an inventory step up charge of $0.5 million, recorded in the first quarter of fiscal year 2014, that are included in our general and administrative expenses and cost of sales, respectively, in our condensed consolidated statements of operations.

	Pro Forma Financial Information
	The following unaudited pro forma information for the three and nine months ended April 30, 2014 and 2013, respectively presents consolidated information as if both the PocketSonics and the Ultrasonix acquisitions occurred on August 1, 2012, which is the first day of our fiscal year 2013:


(in millions, except per share)		For the Three Months Ended								For the Nine Months Ended
(in millions, except per share)		April 30,								April 30,
		2014				2013				2014		2013
Net revenue		$	124			$	128.9			$	375.6	$	407.7
Net income		$	7.8			$	4.8			$	22.7	$	19.4
Net income per share, basic		$	0.63			$	0.39			$	1.83	$	1.58
Net income per share, diluted		$	0.62			$	0.38			$	1.79	$	1.54

Accounts_Receivable_Net

Accounts Receivable, Net	9 Months Ended
Accounts Receivable, Net	Apr. 30, 2014
Accounts Receivable, Net	'
	4. Accounts Receivable, Net
	Our accounts receivable arise primarily from products sold and services provided in the U.S., Europe and Asia. The balance in accounts receivable represents the amount due from our domestic and foreign OEM customers, distributors and end users. The majority of our accounts receivable have standard payment terms that require payment within 30 days. We perform ongoing credit evaluations of our customers’ financial condition and continuously monitor collections and payments from our customers and maintain a provision for estimated credit losses based upon specific customer collection issues that have been identified. We accrue reserves against trade receivables for estimated losses that may result from a customer’s inability to pay. Amounts determined to be uncollectible are charged or written off against the reserve. To date, our historical write-offs of accounts receivable have been minimal.
	Our top ten customers combined accounted for approximately 68% and 67% of our total net revenue for the three months ended April 30, 2014 and 2013, respectively, and 67% and 68% of our total net revenue for the nine months ended April 30, 2014 and 2013, respectively. Set forth in the table below, are customers which individually accounted for 10% or more of our net revenue.


			For the Three Months Ended						For the Nine Months Ended
			April 30,						April 30,
			2014			2013			2014			2013
	Koninklijke Philips Electronics N.V., or Philips			17	%		14	%		17	%		14	%
	L-3 Communications Corporation, or L-3			12	%		13	%		11	%		12	%
	Toshiba Corporation			10	%		*			11	%		11	%
	Siemens AG			12	%		11	%		11	%		*

	Note	(*): Total net revenue was less than 10% in this period.
	The following table summarizes the net accounts receivable due from our customers with net accounts receivable balances greater than or equal to 10% of our total net accounts receivable balance:


			As of			As of
			April 30,			July 31,
			2014			2013
	Philips			22	%		18	%
	L-3			15	%		16	%

Inventory

Inventory	9 Months Ended
Inventory	Apr. 30, 2014
Inventory	'
	5. Inventory
	The components of inventory are summarized as follows:


	(in millions)	As of		As of
		April 30,		July 31,
		2014		2013
	Raw materials	$	58.9	$	78.7
	Work in process		36.4		11.9
	Finished goods		25.1		25.7

	Total inventory	$	120.4	$	116.3

Property_Plant_and_Equipment_N

Property, Plant and Equipment, Net	9 Months Ended
Property, Plant and Equipment, Net	Apr. 30, 2014
Property, Plant and Equipment, Net	'
	6. Property, Plant and Equipment, Net
	Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. The following table summarizes property, plant, and equipment, net:


	(in millions)	Estimated Useful Lives	As of			As of
		(Years)	April 30,			July 31,
			2014			2013
	Land and land improvements	N/A	$	7.6		$	7.4
	Building and improvements	35 to 40		85.2			83
	Leasehold and capital lease improvements	lesser of useful life or the lease term		10.7			10.7
	Manufacturing and engineering equipment	4 to 7		94.8			89.7
	Furniture, fixtures, and computer equipment	3 to 7		34.6			22.9
	Motor vehicles	3 to 5		2.3			2
	Construction in process	N/A		7			13.7
				242.2			229.4
	Less accumulated depreciation and amortization			(128.6	)		(118.4	)
	Total property, plant and equipment, net		$	113.6		$	111
	For the three months ended April 30, 2014 and 2013, total depreciation of property, plant and equipment was $3.5 million and $3.3 million, respectively. For the nine months ended April 30, 2014 and 2013, total depreciation of property, plant and equipment was $10.6 million and $9.7 million, respectively.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	9 Months Ended
Goodwill and Other Intangible Assets	Apr. 30, 2014
Goodwill and Other Intangible Assets	'
	7. Goodwill and Other Intangible Assets
	Goodwill
	The carrying value of our goodwill at April 30, 2014 and July 31, 2013 was $57.0 million and $50.1 million, respectively. The difference between the two periods relates to goodwill associated with the acquisition of PocketSonics of $6.9 million. Upon the acquisition of PocketSonics, we recorded a goodwill asset of $2.8 million, representing the value of the opportunity of further strengthening our competitive position. The goodwill associated with the acquisition was increased by an additional $4.1 million for the deferred tax liability on the IPR&D, upon the acquisition of PocketSonics. Please refer to Note 3. Business Combinations for more information on the acquisition of PocketSonics.
	Other intangible assets
	Other intangible assets include the value assigned to intellectual property and other technology, patents, customer contracts and relationships, tradenames, and IPR&D. Except for IPR&D and one tradename asset, which are considered to have indefinite lives, all intangible assets have estimated useful lives of between 1 and 14 years.
	Other intangible assets are summarized as follows:


		As of April 30, 2014						As of July 31, 2013
	(in millions)	Cost		Accumulated		Net		Cost		Accumulated		Net
	(in millions)	Cost		Amortization		Net		Cost		Amortization		Net
	Developed technologies	$	18.1	$	8.2	$	9.9	$	18.1	$	6.6	$	11.5
	Customer relationships		44		14		30		43.9		10.2		33.7
	Backlog		2.1		2.1		-		2.1		2.1		-
	Tradenames		8.5		0.4		8.1		8.5		0.1		8.4
	In-process research and development		11.5		-		11.5		1.9		-		1.9
	Total intangible assets	$	84.2	$	24.7	$	59.5	$	74.5	$	19	$	55.5
	Amortization expense related to acquired intangible assets was $1.9 million and $5.7 million for the three and nine months ended April 30, 2014, respectively. Amortization expense related to acquired intangible assets was $1.2 million and $2.7 million for the three and nine months ended April 30, 2013, respectively.
	The estimated future amortization expense related to intangible assets for each of the five succeeding fiscal years is expected to be as follows:


	(in millions)	Estimated
		future
		amortization
		expense
	2014 (remaining three months)	$	1.9
	2015		7.6
	2016		6.6
	2017		5.9
	2018		5
	Thereafter		13.3

		$	40.3

	We performed the annual impairment test for our goodwill and other intangible assets with indefinite lives as of December 31, 2013. Goodwill represents the purchase price in excess of the net amount assigned to assets acquired and liabilities assumed by us in connection with historical acquisitions. The goodwill as of December 31, 2013 relates to our acquisitions of Copley Controls in April 2008, Ultrasonix in March 2013, and PocketSonics in September 2013. In accordance with U.S. GAAP, we elected to bypass the qualitative assessment and proceeded to step one of the impairment test by comparing the fair value of the reporting units to their carrying values. A reporting unit, for the purpose of the impairment test, is at or below the operating segment level, and constitutes a business for which discrete financial information is available and regularly reviewed by segment management. The goodwill from the acquisition of Copley Controls, of $1.8 million, is included in our OEM reporting unit under the Medical Imaging segment. For purposes of assessing our annual impairment, the goodwill from the acquisitions of Ultrasonix and PocketSonics, of $55.2 million, is included in our Ultrasound reporting unit. Our impairment assessment considered both the market approach and income approach with different probabilities assigned to each. Under the market approach, the fair value of the reporting unit is based on trading multiples and a control premium, which was determined based on an analysis of control premiums for recent relevant acquisitions. Under the income approach, the fair value of the reporting unit is based on the present value of estimated future cash flows. The income approach is dependent on a number of significant management assumptions including estimates of future sales, future gross margin percentage, and discount rates. We determined that the fair values of the OEM and Ultrasound reporting units were in excess of their carrying values, and therefore it was not necessary for us to perform step two of the impairment test.
	We compared the fair value of the Copley tradename using the relief from royalty approach to its carrying value as of December 31, 2013. The relief from royalty approach utilized an after-tax royalty rate and a discount rate. The after-tax royalty rate was determined based on royalty research and margin analysis while the discount rate was determined after consideration of market rates of return on debt and equity capital, the weighted average return on invested capital and the risk associated with achieving forecasted sales for the Copley tradename. We determined that the fair value of the Copley tradename was in excess of its carrying value.
	Our IPR&D asset arises from our acquisition of PocketSonics. We compared the fair value of the IPR&D using the income approach to its carrying value at December 31, 2013 and determined there was no impairment. We determined the fair value of the IPR&D using a probability-adjusted cash flow model. We expect to begin amortizing the IPR&D over the product life cycle once production of the product begins, which is expected to be within the next three to six months. We expect to utilize this IPR&D asset in our Ultrasound segment.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Apr. 30, 2014
Fair Value Measurements	'
	8. Fair Value Measurements
	Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in a principal or the most advantageous market for the asset transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:

		•		Level 1 – Quoted prices in active markets for identical assets or liabilities.

		•		Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

		•		Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:


	(in millions)		As of		Quoted		Significant		Significant
			April 30,		Prices in		Other		Unobservable
			2014		Active		Observable		Inputs
					Markets		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Assets
	Cash equivalents		$	0.6	$	-	$	0.6	$	-
	Plan assets for deferred compensation			3.5		3.5		-		-
	Total assets at fair value		$	4.1	$	3.5	$	0.6	$	-
	Liabilities
	Contingent consideration		$	2.1	$	-	$	-	$	2.1
	Total liabilities at fair value		$	2.1	$	-	$	-	$	2.1

	(in millions)		As of		Quoted		Significant		Significant
			July 31,		Prices in		Other		Unobservable
			2013		Active		Observable		Inputs
					Markets		Inputs		(Level 3)
					(Level 1)		(Level 2)
	Assets
	Cash equivalents		$	0.8	$	-	$	0.8	$	-
	Plan assets for deferred compensation			2.7		2.7		-		-
	Total assets at fair value		$	3.5	$	2.7	$	0.8	$	-
	Liabilities
	Foreign currency forward contracts		$	0.2	$	-	$	0.2	$	-
	Total liabilities at fair value		$	0.2	$	-	$	0.2	$	-
	Assets held in the deferred compensation plans will be used to pay benefits under our non-qualified deferred compensation plans. The investments primarily consist of mutual funds which are publicly traded on stock exchanges. Accordingly, the fair value of these assets are categorized as Level 1 within the fair value hierarchy.
	Our cash equivalents consist of highly liquid demand deposits. The fair value of these deposits, which is determined by projecting future cash flows using an estimated economic life, does not deviate from the face value. Accordingly, the fair value of these assets are categorized as Level 2 within the fair value hierarchy.
	The fair value of the liabilities arising from our foreign currency forward contracts is determined by valuation models based on market observable inputs, including forward and spot prices for currencies. Accordingly, the fair value of these liabilities are categorized as Level 2 within the fair value hierarchy.
	The fair value of our contingent consideration obligation is based on significant unobservable inputs, including management estimates and assumptions, and is measured based on the probability-weighted present value of the payments expected to be made. Accordingly, the fair value of these liabilities are categorized as Level 3 within the fair value hierarchy.
	The fair value of the contingent payments associated with the acquisition of PocketSonics was calculated utilizing 100% for the earnout associated with commercial launch as a result of 510(k) clearance from the Food and Drug Administration, or FDA, on April 9, 2014 and the anticipation of commercial launch in the first quarter of fiscal year 2015. As of April 30, 2014, the fair value of the contingent consideration payments associated with the sales volume target earnout was calculated utilizing a discount rate of 27.0%. Each quarter we revalue the contingent consideration obligations associated with the acquisition of PocketSonics to its then current fair value and record changes in the fair value to the statement of operations. Changes in contingent consideration expense result from changes in the assumptions regarding probabilities of the estimated timing of launch, volume sales target, payments and the discount rate used to estimate the fair value of the liability. The assumptions used in estimating fair value require significant judgment. The use of different assumptions and judgments could result in a materially different estimate of fair value.
	The following table reconciles the changes in the fair value of contingent consideration obligations that are categorized as Level 3 within the fair value hierarchy:


			For the Three Months Ended		For the Nine Months Ended
			April 30,		April 30,
	(in millions)		2014		2014
	Fair value, beginning of period		$	2	$	-
	Acquisition date fair value of contingent consideration			-		1.9
	Change in fair value			0.1		0.2
	Payments			-		-
	Fair value, end of period		$	2.1	$	2.1
	We have an equity investment in a privately-held company which is accounted for under the cost method. The carrying value of this investment is zero.

Derivative_Instruments

Derivative Instruments	9 Months Ended
Derivative Instruments	Apr. 30, 2014
Derivative Instruments	'
	9. Derivative Instruments
	Certain of our foreign operations have revenue and/or expenses transacted in currencies other than the U.S. dollar. In order to mitigate foreign currency exchange risk, we use forward contracts to lock in exchange rates associated with a portion of our forecasted international expenses.
	As of April 30, 2014, we had forward contracts outstanding with notional amounts totaling $3.0 million in the Canadian dollar. These contracts have been designated as cash flow hedges and the unrealized loss of less than $0.1 million, net of tax, on these contracts is reported in accumulated other comprehensive income. Asset and liability derivatives designated as hedging instruments are presented in other assets and other liabilities, respectively, on our consolidated balance sheets. Realized gains (losses) on the cash flow hedges are recognized in our consolidated statement of operations in the period when the payment of expenses is recognized. During the three and nine months ended April 30, 2014 and 2013, we recorded a realized gain (loss) of approximately $0.1 million and $(0.1) million, and $(0.2) million and $0.1 million, respectively, which were included in cost of revenue and operating expenses in our condensed consolidated statements of operations. We expect all contracts currently outstanding to settle as of July 31, 2014 and any amounts in accumulated other comprehensive income (loss) to be recorded as an adjustment to operating expenses.

Common_Stock_Repurchases

Common Stock Repurchases	9 Months Ended
Common Stock Repurchases	Apr. 30, 2014
Common Stock Repurchases	'
	10. Common Stock Repurchases
	On December 8, 2011, we announced that our board of directors had authorized the repurchase of up to $30.0 million of our common stock. The repurchase program is funded using our available cash. During the three and nine months ended April 30, 2014, we repurchased and retired 43,740 shares and 125,928 shares of common stock, respectively, under this repurchase program for $3.6 million and $10.6 million, respectively, at an average purchase price of $82.65 per share and $83.98 per share, respectively. During the three and nine months ended April 30, 2013, we repurchased and retired zero shares and 85,327 shares of common stock, respectively, under this repurchase program for $0.0 million and $6.0 million, respectively, at an average purchase price of $0.00 and $70.56 per share, respectively. As of April 30, 2014, we have cumulatively repurchased and retired 375,335 shares of common stock under this repurchase program for $27.0 million at an average purchase price of $71.86 per share.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	9 Months Ended
Accumulated Other Comprehensive Income	Apr. 30, 2014
Accumulated Other Comprehensive Income	'
	11. Accumulated Other Comprehensive Income
	Components of comprehensive income include net income and certain transactions that have generally been reported in the consolidated statements of changes in stockholders’ equity. Other comprehensive income consists of reported foreign currency translation gains and losses (net of taxes), actuarial gains and losses on pension plan assets (net of taxes), and changes in the unrealized value on foreign currency forward contracts (net of taxes). Deferred taxes are not provided on cumulative translation adjustments where we expect earnings of a foreign subsidiary to be indefinitely reinvested. The income tax effect of currency translation adjustments related to foreign subsidiaries that are not considered indefinitely reinvested is recorded as a component of deferred taxes with an offset to other comprehensive income.
	The following table summarizes components of accumulated other comprehensive income for the nine months ended April 30, 2013:


	(in millions)	Unrealized			Unrealized			Currency		Accumulated
		Gains			Gains			Translation		Other
		(Losses) on			(Losses) on					Comprehensive
		Foreign			Pension Plan					Income
		Currency
		Forward
		Contracts
	Balance as of July 31, 2012	$	-		$	(4.7	)	$	7	$	2.3
	Pre-tax change before reclass to earnings		(0.1	)		-			4		3.9
	Amount reclassed to earnings (Note 9)		0.1			-			-		0.1
	Income tax benefit		-			-			0.3		0.3
	Balance as of April 30, 2013	$	-		$	(4.7	)	$	11.3	$	6.6
	The following table summarizes components of accumulated other comprehensive income for the nine months ended April 30, 2014:


	(in millions)	Unrealized			Unrealized			Currency		Accumulated
		Gains			Gains			Translation		Other
		(Losses) on			(Losses) on					Comprehensive
		Foreign			Pension Plan					Income
		Currency
		Forward
		Contracts
	Balance as of July 31, 2013	$	(0.1	)	$	(2.3	)	$	11.5	$	9.1
	Pre-tax change before reclass to earnings		-			-			1.4		1.4
	Amount reclassed to earnings (Note 9)		0.2			-			-		0.2
	Income tax benefit		-			-			0.1		0.1
	Balance as of April 30, 2014	$	0.1		$	(2.3	)	$	13	$	10.8
	The ineffective portion of the unrealized gains or losses on foreign currency forward contracts and unrealized gains or losses on currency translation are included in other income (expenses), net on our condensed consolidated statement of operations.

Sharebased_Compensation

Share-based Compensation	9 Months Ended
Share-based Compensation	Apr. 30, 2014
Share-based Compensation	'
	12. Share-based Compensation
	On January 29, 2010, our stockholders approved a share-based compensation plan named the “2009 Stock Incentive Plan”, or 2009 Plan, which provided for the issuance of up to 1,600,000 shares of common stock. Stockholders approved amendments to the 2009 Plan on January 23, 2012 and January 21, 2014 which included increasing the number of shares available for issuance to 2,200,000 and 4,453,518, respectively.
	On November 4, 1985, our stockholders approved an employee stock purchase plan named the “Employee Stock Purchase Plan”, or ESPP, of up to 700,000 shares of common stock. Stockholders approved amendments to the ESPP on January 21, 1986, October 9, 1997, and October 15, 2002. On January 21, 2014, our stockholders approved amendments to the ESPP which included expanding the employees eligible to participate to include “highly compensated employees” as well as increasing the maximum value of stock that each employee can purchase from $2,600 to $12,500 in each of the two payment periods per year.
	Share-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period, net of forfeitures.
	The following table presents share-based compensation expense included in our condensed consolidated statements of operations:


			For the Three Months Ended						For the Nine Months Ended
			April 30,						April 30,
	(in millions)		2014			2013			2014			2013
	Cost of product sales		$	0.1		$	0.2		$	0.5		$	0.6
	Cost of engineering sales			0.1			0.2			0.3			0.9
	Research and product development			0.5			0.3			2			1.5
	Selling and marketing			0.3			0.2			0.9			0.7
	General and administrative			1.9			1.1			5			4.3
	Total share-based compensation expense before tax			2.9			2			8.7			8
	Income tax effect			(0.9	)		(0.5	)		(2.7	)		(2.5	)
	Share-based compensation expense included in net income		$	2		$	1.5			6		$	5.5
	Stock options
	We estimate the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, the expected option term, the expected volatility of our stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and our expected annual dividend yield. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards.
	We had no material grants of stock options during the three months ended April 30, 2014. The fair value of each option granted during the three and nine months ended April 30, 2014 and 2013 was estimated on the grant date using the Black-Scholes valuation model with the following assumptions:


			For the Three Months Ended						For the Nine Months Ended
			April 30,						April 30,
			2014			2013			2014			2013
	Expected option term in years (1)			5.31			5.47			5.37			5.42
	Expected volatility (2)			35.1	%		41	%		38.6	%		41	%
	Risk-free interest rate (3)			1.51	%		0.91	%		1.77	%		0.8	%
	Expected annual dividend yield (4)			0.42	%		0.52	%		0.52	%		0.57	%

	-1	The expected option term was estimated using historical data.
	-2	The expected volatility for each grant is determined based on the review of the average of historical daily price changes of our common stock over the expected option term.
	-3	The risk-free interest rate is determined based on the yield of zero-coupon U.S. Treasury securities for a period that is commensurate with the expected term assumption.
	-4	The expected annual dividend yield is calculated by dividing the expected annual dividends by the stock price on the date of grant.
	The weighted average grant date fair value of stock options that were granted during the three and nine months ended April 30, 2014 was $30.80 and $27.55, respectively. The weighted average grant date fair value of stock options that were granted during the three and nine months ended April 30, 2013 was $27.90 and $25.25, respectively.
	The total intrinsic value of options exercised during the three and nine months ended April 30, 2014, was $0.1 million and $1.7 million, respectively, with intrinsic value defined as the difference between the market price on the date of exercise and the grant date exercise price.
	As of April 30, 2014, 402,950 stock options were vested or expected to vest and 177,567 stock options were exercisable. These options have a weighted average exercise price of $63.34, and $55.67, respectively, aggregate intrinsic value of $5.0 million and $3.5 million, respectively, and a weighted average remaining contractual term of 5.12 years and 4.10 years, respectively.
	We estimate the fair value of ESPP shares using the Black-Scholes valuation model. For the three and nine months ended April 30, 2014 and 2013, the financial impact from ESPP shares was immaterial.

	Restricted stock and restricted stock units
	We estimate the fair value of restricted stock and restricted stock units, or RSU’s, that vest based on service conditions using the quoted closing price of our common stock on the date of grant. Share-based compensation expense is amortized over each award’s vesting period on a straight-line basis for all awards with service conditions, while the graded vesting method applies to all awards with both service and performance conditions.
	For our non-GAAP earnings per share, or EPS, performance-based awards, the compensation cost is amortized over the performance period on a straight-line basis, net of forfeitures, because such awards vest only at the end of the performance period. The compensation cost is based on the number of shares that are deemed probable of vesting at the end of the three-year performance cycle. This probability assessment is done each quarter and changes in estimates can result in significant expense fluctuations due to the cumulative catch-up adjustment. We estimate the fair value of the non-GAAP EPS performance-based awards using the quoted closing price of our common stock on the date of grant.
	For our relative total shareholder return, or TSR, performance-based awards, which are based on market performance, the compensation cost is amortized over the performance period on a straight-line basis net of forfeitures, because the awards vest only at the end of the measurement period and the probability of actual shares expected to be earned is considered in the grant date valuation. As a result, the expense is not adjusted to reflect the actual shares earned. We estimate the fair value of the TSR performance-based awards using the Monte-Carlo simulation model.
	We granted 95 TSR and 124 non-GAAP EPS performance-based awards during the three months ended April 30, 2014. We granted 413 TSR and 537 non-GAAP EPS performance-based awards during the three months ended April 30, 2013. The fair value of our TSR performance-based awards at the date of grant was estimated using the Monte-Carlo simulation model with the following assumptions:


			For the Three Months Ended						For the Nine Months Ended
			April 30,						April 30,
			2014			2013			2014			2013
	Stock Price (1)		$	94.32		$	70.04		$	77.14		$	70.04
	Expected volatility (2)			27.5	%		28	%		27.6	%		28	%
	Risk-free interest rate (3)			0.46	%		0.32	%		0.82	%		0.32	%
	Expected annual dividend yield (4)			0	%		0	%		0	%		0	%

	-1	The stock price is the closing price of our common stock on the date of grant.
	-2	The expected volatility for each grant is determined based on the historical volatility for the peer group companies and our common stock over a period equal to the remaining term of the performance period from the date of grant for all awards.
	-3	The risk free interest rate is determined based on the yield of zero-coupon U.S. Treasury securities for a period that is commensurate with the performance period.
	-4	Dividends are considered reinvested when calculating TSR. The dividend yield is therefore considered to be 0%.
	The weighted average grant date fair value of time-based restricted stock awards that were granted during the three and nine months ended April 30, 2014 was $95.49 and $82.46, respectively. The weighted average grant date fair value of performance-based restricted stock awards that were granted during the three and nine months ended April 30, 2014 was $117.61 and $93.85, respectively.
	The total fair value of restricted stock shares that vested during the three and nine month periods ended April 30, 2014 was $0.7 million and $20.8 million, respectively.
	As of April 30, 2014, the unrecognized compensation cost, net of estimated forfeitures, related to unvested stock options and restricted stock was $13.4 million. This cost will be recognized over an estimated weighted average amortization period of 1.5 years and assumes target performance for the non-GAAP EPS performance-based RSU’s.

Restructuring_Charges

Restructuring Charges	9 Months Ended
Restructuring Charges	Apr. 30, 2014
Restructuring Charges	'
	13. Restructuring Charges
	During fiscal year 2013, we implemented a restructuring plan that involved involuntary termination of 115 employees, as well as consolidation of manufacturing and certain support activities conducted at the Ultrasonix facility in Vancouver, Canada, into operations at our existing facilities, closure of the Ultrasonix sales subsidiary in Paris, France, closure of our Englewood, Colorado facility (which was closed in January 2014) as we consolidate manufacturing and development activities into our State College, Pennsylvania facility, and optimization of our operations in Montreal, Canada and Peabody, Massachusetts.
	The following table summarizes charges related to the accrued restructuring activities during the three and nine months ended April 30, 2014.


	(in millions)	Employee			Facility			Acquisition			Total
		Severance			Exit			Related
		and Benefits			Costs			Charges
	Balance at July 31, 2013	$	1.8		$	0.2		$	0.8		$	2.8
	Restructuring charge		0.2			-			0.1			0.3
	Adjustments		(0.2	)		-			(0.1	)		(0.3	)
	Cash payments		(0.5	)		-			(0.1	)		(0.6	)
	Currency translation		-			-			-			-
	Balance at October 31, 2013	$	1.3		$	0.2		$	0.7		$	2.2
	Restructuring charge		-			0.6			-			0.6
	Adjustments		(0.2	)		(0.1	)		-			(0.3	)
	Cash payments		(0.6	)		-			(0.4	)		(1.0	)
	Currency translation		-			-			-			-
	Balance at January 31, 2014	$	0.5		$	0.7		$	0.3		$	1.5
	Restructuring charge		-			-			0.1			0.1
	Adjustments		-			-			(0.2	)		(0.2	)
	Cash payments		(0.3	)		(0.1	)		(0.1	)		(0.5	)
	Currency translation		-			-			-			-
	Balance at April 30, 2014	$	0.2		$	0.6		$	0.1		$	0.9
	The following table summarizes charges related to the accrued restructuring activities during the nine months ended April 30, 2013.


	(in millions)	Employee			Facility			Acquisition			Total
		Severance			Exit			Related
		and Benefits			Costs			Charges
	Balance at July 31, 2012	$	-		$	-		$	-		$	-
	Restructuring charge		0.1			-			0.4			0.5
	Adjustments		-			-			-			-
	Cash payments		-			-			-			-
	Currency translation		-			-			-			-
	Balance at April 30, 2013	$	0.1		$	-		$	0.4		$	0.5
	There were no restructuring charges for the three and six months ended January 31, 2013.
	Restructuring and related charges, including actions associated with acquisitions, by segment are as follows:


		For the Three Months Ended						For the Nine Months Ended
		April 30,						April 30,
	(in millions)	2014			2013			2014			2013
	Medical Imaging	$	-		$	0.1		$	(0.2	)	$	0.1
	Ultrasound		(0.1	)		0.4			0.4			0.4
	Security Technology		-			-			-			-
	Total restructuring and related charges	$	(0.1	)	$	0.5		$	0.2		$	0.5

Net_Income_Per_Common_Share

Net Income Per Common Share	9 Months Ended
Net Income Per Common Share	Apr. 30, 2014
Net Income Per Common Share	'
	14. Net Income Per Common Share
	Basic net income per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net income per share is computed using the sum of the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock, including unvested restricted stock and the assumed exercise of stock options using the treasury stock method. Options to purchase common shares with exercise prices that exceeded the market value of the underlying common stock are excluded from the computation of diluted earnings per share. Application of the treasury stock method could be anti-dilutive to unvested restricted shares if due to unrecognized compensation and windfall tax benefit the hypothetical repurchase of shares exceeds the number of restricted shares to be exercised.
	Basic and diluted net income per share are calculated as follows:


		For the Three Months Ended				For the Nine Months Ended
		April 30,				April 30,
	(in millions)	2014		2013		2014		2013
	Net income	$	7.8	$	5.2	$	23.3	$	19.4

	Weighted-average number of common shares outstanding-basic (000’s)		12,403		12,305		12,421		12,300
	Effect of dilutive securities:
	Stock options and restricted stock units (000’s)		244		315		258		284
	Weighted-average number of common shares outstanding-diluted (000’s)	$	12,647	$	12,620	$	12,679	$	12,584

	Basic net income per share:	$	0.63	$	0.42	$	1.88	$	1.58
	Diluted net income per share:	$	0.62	$	0.41	$	1.84	$	1.54
	For the three months ended April 30, 2014 and 2013, approximately 123,000 and 107,000 potentially dilutive shares, respectively, were excluded from the computation of diluted earnings per share as the effect would be anti-dilutive. For the nine months ended April 30, 2014 and 2013, approximately 109,000 and 102,000 potentially dilutive shares, respectively, were excluded from the computation of diluted earnings per share as the effect would be anti-dilutive.

Income_Taxes

Income Taxes	9 Months Ended
Income Taxes	Apr. 30, 2014
Income Taxes	'
	15. Income Taxes
	The following table presents the provision for (benefit from) income taxes and our effective tax rate for the three and nine months ended April 30, 2014 and 2013:


		For the Three Months Ended						For the Nine Months Ended
		April 30,						April 30,
	(in millions)	2014			2013			2014			2013
	Provision for (benefit from) income taxes	$	2.5		$	1.7		$	(6.1	)	$	7.4
	Effective tax rate		24	%		24	%		-35	%		28	%
	The effective income tax rate is based upon the estimated income for the year, the composition of the income in different countries, and adjustments, if any, in the applicable quarterly periods for the potential tax consequences, benefits, resolution of tax audits, tax contingencies or other discrete items.
	Our effective tax rate before discrete items for the three and nine months ended April 30, 2014, respectively, is lower than the statutory rate of 35%, primarily due to lower foreign tax rates, and tax credits in the U.S. and Canada. The tax provision for the three and nine months ended April 30, 2014 includes certain discrete tax benefits totaling $0.0 million and $10.6 million, respectively. The discrete items for the three months ended April 30, 2014 consist of favorable changes in reserves for uncertain tax positions totaling $0.2 million resulting from accretion of interest, expiration of the statute of limitations and other items, as well as $0.6 million of an unfavorable adjustment to a deferred item related to equity compensation, and $0.4 million in miscellaneous favorable discrete items. The discrete tax benefit for the nine months ended April 30, 2014, consists primarily of a reduction in a net deferred tax liability of $8.8 million associated with a change in classification of our Canadian operations, and a reduction in uncertain tax positions primarily associated with federal tax credits for research and development, or R&D, for $0.9 million following the conclusion of the Internal Revenue Service, or IRS, review for the fiscal year 2009, along with $0.9 million of other items.
	The effective tax rate for the three and nine months ended April 30, 2013 was lower than the federal statutory rate due primarily to lower foreign tax rates and the extension of the federal R&D tax credit.

	The effective tax rate was lower in the nine months ended April 30, 2014 versus the prior year comparable period, due to the impact of discrete items in fiscal year 2014.
	The total amounts of gross unrecognized tax benefits, which excludes interest and penalties discussed below, as of April 30, 2014 and July 31, 2013 were as follows:


	(in millions)	April 30, 2014			July 31, 2013
	Gross unrecognized tax benefits	$	6.6		$	7.3
	These unrecognized tax benefits, if recognized in a future period, the timing of which is not estimable, would favorably impact our effective tax rate. In the next four quarters, the statute of limitations for our fiscal year ended July 31, 2011 may expire for federal and state income taxes and for our fiscal year ended July 31, 2007 for foreign subsidiaries. It is reasonably expected that net unrecognized tax benefits, including interest, of approximately $3.0 million may be recognized.
	We accrue interest and, if applicable, penalties for any uncertain tax positions. This interest and penalty expense is treated as a component of income tax expense. At April 30, 2014 and April 30, 2013, we had approximately $0.6 million and $0.7 million, respectively, accrued for interest and penalties on unrecognized tax benefits.
	We do not provide for U.S. federal income taxes on undistributed earnings of consolidated foreign subsidiaries; as such earnings are intended to be indefinitely reinvested in those operations. Determination of the potential deferred income tax liability on these undistributed earnings is not practicable because such liability, if any, is dependent on circumstances that exist if and when remittance occurs. The circumstances that would affect the calculations would be the source location and amount of the distribution, the underlying tax rate already paid on the earnings, foreign withholding taxes and the opportunity to use foreign tax credits in the U.S.
	We are subject to U.S. federal income tax as well as the income tax of multiple state and foreign jurisdictions. As of April 30, 2014, we have closed all years for U.S. federal income tax purposes through the fiscal year ended July 31, 2010. We are subject to periodic tax audits in each of the jurisdictions in which we operate. We are currently under a limited transfer pricing audit in Denmark for fiscal years 2008 through 2011. We have received an initial assessment from the Danish taxing authorities and are currently disputing the findings of that assessment. Discussions with the Danish taxing authorities are ongoing and we have recorded an accrual accordingly.

Segment_Information

Segment Information	9 Months Ended
Segment Information	Apr. 30, 2014
Segment Information	'
	16. Segment Information:
	Our business is strategically aligned into three segments: Medical Imaging, Ultrasound, and Security Technology. Our business segments are described below.

		•		Medical Imaging, which primarily includes systems and subsystems for CT and MRI medical imaging equipment as well as state-of-the-art, selenium-based detectors for screening of breast cancer and other diagnostic applications in mammography.

		•		Ultrasound, which includes ultrasound systems and transducers used primarily in the urology, surgery (including robotic assisted surgery), anesthesia, and point-of-care markets.

		•		Security Technology, which includes advanced threat detecting CT systems utilizing our expertise in advanced imaging technology, primarily used in checked baggage screening at airports worldwide.

	The tables below present information about our reportable segments:


			For the Three Months Ended						For the Nine Months Ended
			April 30,						April 30,
	(in millions)		2014			2013			2014			2013
	Product revenue:
	Medical Imaging		$	70.7		$	68.8		$	208.3		$	218.5
	Ultrasound			37.3			33.9			112.1			106
	Security Technology			14.1			18.5			49.6			42
	Total product revenue		$	122.1		$	121.2		$	370		$	366.5
	Engineering revenue:
	Medical Imaging		$	1		$	2.9		$	3.2		$	9.9
	Ultrasound			-			0.1			-			0.1
	Security Technology			1			1.6			2.4			7.7
	Total engineering revenue		$	2		$	4.6		$	5.6		$	17.7
	Net revenue:
	Medical Imaging		$	71.7		$	71.7		$	211.5		$	228.4
	Ultrasound			37.3			34			112.1			106.1
	Security Technology			15.1			20.1			52			49.7
	Total net revenue		$	124.1		$	125.8		$	375.6		$	384.2
	Income from operations:
	Medical Imaging		$	8.9		$	6.5		$	19.3		$	22.4
	Ultrasound			(1.3	)		(4.4	)		(6.1	)		(1.7	)
	Security Technology			1.8			4.6			3.9			7.2
	Total income from operations			9.4			6.7			17.1			27.9
	Total other income (expenses), net			0.9			0.2			0.1			(1.1	)
	Income before income taxes		$	10.3		$	6.9		$	17.2		$	26.8


			As of			As of
			April 30,			July 31,
	(in millions)		2014			2013
	Identifiable assets by segment:
	Medical Imaging		$	215.8		$	217.1
	Ultrasound			221.7			218.4
	Security Technology			32.9			53.4
	Total reportable segment assets			470.4			488.9
	Corporate assets (A)			132			98.9
	Total assets		$	602.4		$	587.8


			As of			As of
			April 30,			July 31,
	(in millions)		2014			2013
	Goodwill by segment:
	Medical Imaging		$	1.9		$	1.9
	Ultrasound			48.2			48.2
	Security Technology			-			-
	Corporate (B)			6.9			-
	Total goodwill		$	57		$	50.1

	(A)	Includes cash and cash equivalents of $73.5 million and $57.4 million as of April 30, 2014 and July 31, 2013, respectively.
	(B)	Includes goodwill related to the acquisition of PocketSonics. Please see Note 7. Goodwill and Other Intangible Assets for further discussion on PocketSonics.

Other_Income_Expenses_Net

Other Income (Expenses), Net	9 Months Ended
Other Income (Expenses), Net	Apr. 30, 2014
Other Income (Expenses), Net	'
	17. Other Income (Expenses), Net:
	Other income (expenses), net consists primarily of interest income on cash equivalents, loss on investment, and foreign exchange gains (losses).
	Related to the acquisition of PocketSonics, we recognized a loss of $0.5 million during the first quarter of fiscal year 2014. Please refer to Note 3. Business Combinations for more information on the acquisition of PocketSonics.
	We had foreign exchange (gains) losses totaling $(0.4) million and $0.1 million during the three and nine months ended April 30, 2014, respectively. We had foreign exchange (gains) losses totaling $(0.2) million and $1.3 million during the three and nine months ended April 30, 2013, respectively.

Guarantees_Commitments_and_Con

Guarantees, Commitments and Contingencies	9 Months Ended
	Apr. 30, 2014
Guarantees, Commitments and Contingencies	'
	18. Guarantees, Commitments and Contingencies:
	Guarantees and Indemnification Obligations
	Our standard OEM and supply agreements entered in the ordinary course of business typically contain an indemnification provision pursuant to which we indemnify, hold harmless, and agree to reimburse the indemnified party for losses suffered or incurred by the indemnified party in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to our products. Such provisions generally survive termination or expiration of the agreements. The potential amount of future payments we could be required to make under these indemnification provisions is, in some instances, unlimited. Our costs to defend lawsuits or settle claims related to these indemnification agreements have been insignificant to date. As a result, we believe that our estimated exposure on these agreements is currently minimal. Accordingly, we have no liabilities recorded for these agreements as of April 30, 2014.
	Generally, we warrant that our products will perform in all material respects in accordance with our standard published specifications in effect at the time of delivery of the products to the customer for a period ranging from 12 to 36 months from the date of delivery. We provide for the estimated cost of product and service warranties based on specific warranty claims, claim history, and engineering estimates, where applicable.
	The following table presents our product warranty liability for the nine months ended April 30, 2014 and the twelve months ended July 31, 2013:


	(in millions)		As of			As of
			April 30,			July 31,
			2014			2013
	Product warranty liability, beginning balance		$	6.5		$	5.6
	Provision
	Provision			3.1			5.3
	Ultrasonix warranty accrual acquired			-			1.2
	Settlements made in cash or in kind during the period			(3.4	)		(5.6	)
	Product warranty liability, ending balance		$	6.2		$	6.5
	At April 30, 2014 and July 31, 2013, we had deferred revenue for extended product warranty contracts of $9.2 million and $8.0 million, respectively.
	Revolving Credit Agreements
	On October 11, 2011, we entered into a $100.0 million five-year, revolving credit agreement, or Credit Agreement, with the financial institutions identified therein as lenders, which included Santander Bank, TD Bank, N.A., and HSBC Bank USA, National Association. The Credit Agreement provides $100.0 million in available credit and expires on October 10, 2016, when all outstanding borrowings will be payable in full. The credit facility does not require amortization of principal and may be reduced before maturity in whole or in part at our option without penalty.
	Borrowings under the Credit Agreement may be used for general corporate purposes, including permitted acquisitions. The amount of available credit can be increased under specified circumstances up to $150.0 million in aggregate. We are the sole borrower under the Credit Agreement. The obligations under the new credit facility are guaranteed by our material domestic subsidiaries and are supported by a pledge of 65% of the capital stock and equity equivalents of our principal international subsidiaries.

	Interest rates on borrowings outstanding under the credit facility would range from 1.25% to 2.00% above the LIBOR rate, or, at our option would range from 0.00% to 1.00% above the defined base rate, in each case based upon our leverage ratio. A quarterly commitment fee ranging from 0.20% to 0.35% per annum is applicable on the undrawn portion of the credit facility, based upon our leverage ratio.
	The Credit Agreement limits us and our subsidiaries’ ability to, among other things: incur additional indebtedness; incur liens or guarantee obligations; pay dividends or make other distributions; make investments; dispose of assets; and engage in transactions with affiliates except on an arms-length basis. In addition, the Credit Agreement requires us to maintain the following financial ratios.

		•		A leverage ratio, defined as consolidated funded indebtedness to consolidated trailing four quarters earnings before interest, taxes, depreciation, and amortization, or EBITDA, of no greater than 2.75:1.00 at any time; and

		•		An interest coverage ratio, defined as the ratio of consolidated trailing four quarters EBITDA to consolidated interest charges of no less than 3.00:1.00 at any time.
	As of April 30, 2014 our leverage ratio was .006 and our interest coverage ratio was not applicable as we had no attributable interest expense. As of April 30, 2014, we were in full compliance with all financial and operating covenants.
	Any failure to comply with the financial or operating covenants of the credit facility would prevent us from being able to borrow and would also constitute a default, permitting the lenders to, among other things, accelerate repayment of outstanding borrowings, including all accrued interest and fees, and to terminate the credit facility. A change in control of us, as defined in the Credit Agreement, would also constitute an event of default, permitting the lenders to accelerate repayment and terminate the Credit Agreement.
	In connection with entering into this facility, we incurred approximately $0.5 million of transactions costs, which are being expensed over the five-year life of the credit facility.
	As of April 30, 2014, we have approximately $4.2 million in other revolving credit facilities with banks available for direct borrowings.
	We did not have any borrowing outstanding under our credit facilities at April 30, 2014 and July 31, 2013.
	Legal Claims
	We are subject to litigation, claims, investigations and audits arising from time to time in the ordinary course of our business. Although legal proceedings are inherently unpredictable, we believe that we have valid defenses with respect to those matters currently pending against us and intend to defend ourselves vigorously. The outcome of these matters, individually and in the aggregate, is not expected to have a material impact on our cash flows, results of operations, or financial position. In addition to litigation claims, investigations, and audits arising in the normal course of business, we are also subject to an investigation regarding our Danish subsidiary. Please refer to the following disclosure for more details regarding the investigation of our Danish subsidiary. We record losses when estimable and probable in accordance with U.S. GAAP.
	Investigation Regarding our Danish Subsidiary
	As initially disclosed in our Annual Report on Form 10-K for the fiscal year ended July 31, 2011, we identified certain transactions involving our Danish subsidiary BK Medical ApS, or BK Medical, and certain of its foreign distributors, with respect to which we have raised questions concerning compliance with law, including Danish law and the U.S. Foreign Corrupt Practices Act, and our business policies. These have included transactions in which the distributors paid BK Medical amounts in excess of amounts owed and BK Medical transferred the excess amounts, at the direction of the distributors, to third parties identified by the distributors. We have terminated the employment of certain BK Medical employees and have wound down the relationships with the BK Medical distributors that were involved in the transactions. However, we have been unable to ascertain with certainty the ultimate beneficiaries or the purpose of these transfers. We have voluntarily disclosed this matter to the Danish Government, the U.S. Department of Justice, or DOJ, and the SEC and are cooperating with inquiries by the Danish Government, the DOJ and the SEC. We are unable to estimate the potential penalties and/or sanctions, if any, that might be assessed in connection with these matters. We have concluded that the transactions identified to date have been properly accounted for in our reported financial statements in all material respects. During the three months ended April 30, 2014 and April 30, 2013, we incurred inquiry-related costs of approximately $0.4 million and $0.3 million, respectively, in connection with this matter. During the nine months ended April 30, 2014 and April 30, 2013, we incurred inquiry-related costs of approximately $1.3 million and $0.7 million, respectively, in connection with this matter.

Leases_and_Other_Commitments

Leases and Other Commitments	9 Months Ended
Leases and Other Commitments	Apr. 30, 2014
Leases and Other Commitments	'
	19. Leases and Other Commitments:
	Certain of our subsidiaries lease manufacturing and office space under non-cancelable operating leases. These leases contain renewal options. We lease certain other real property and equipment under operating leases which, in the aggregate, are not significant.
	Rent expense associated with our operating leases was approximately $0.4 million and $0.5 million for the three months ended April 30, 2014 and 2013, respectively. Rent expense associated with our operating leases was approximately $1.6 million and $1.2 million for the nine months ended April 30, 2014 and 2013, respectively.
	The following is a schedule by year of future minimum lease payments at April 30, 2014:


	(in millions)	Future Minimum Lease
	Fiscal Year	Payments
	2014 (3 months)	$	0.8
	2015		2.1
	2016		1.3
	2017		0.9
	2018		0.7
	Thereafter		1.2

		$	7

	At April 30, 2014, we had outstanding non-cancelable purchase orders aggregating to $55.7 million. The purchase orders are for manufacturing and non-manufacturing related goods and services.

Subsequent_Events

Subsequent Events	9 Months Ended
Subsequent Events	Apr. 30, 2014
Subsequent Events	'
	20. Subsequent Events:
	On June 3, 2014, our board of directors authorized an additional repurchase of up to $30.0 million of our common stock. The repurchase program will be funded by our available cash. The repurchase program does not have a fixed expiration date.
	We declared a dividend of $0.10 per share of common stock on June 3, 2014, which will be paid on June 26, 2014 to stockholders of record on June 16, 2014.

Business_Combinations_Tables

Business Combinations (Tables)	9 Months Ended
Business Combinations (Tables)	Apr. 30, 2014
Unaudited Pro Forma Information	'
	The following unaudited pro forma information for the three and nine months ended April 30, 2014 and 2013, respectively presents consolidated information as if both the PocketSonics and the Ultrasonix acquisitions occurred on August 1, 2012, which is the first day of our fiscal year 2013:


	(in millions, except per share)		For the Three Months Ended						For the Nine Months Ended
	(in millions, except per share)		April 30,						April 30,
			2014			2013			2014		2013
	Net revenue		$	124		$	128.9		$	375.6	$	407.7
	Net income		$	7.8		$	4.8		$	22.7	$	19.4
	Net income per share, basic		$	0.63		$	0.39		$	1.83	$	1.58
	Net income per share, diluted		$	0.62		$	0.38		$	1.79	$	1.54
PocketSonics	'
Summary of Estimated Fair Values of Separately Identifiable Assets Acquired and Liabilities Assumed	'
	The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of September 20, 2013:


	(in millions)
	Cash		$	0.5
	Goodwill			6.9
	IPR&D			11.5

	Total assets acquired			18.9
	Accounts payable and accrued expenses			(0.3	)
	Deferred taxes			(4.1	)

	Total liabilities assumed			(4.4	)

	Total purchase price		$	14.5

Ultrasonix	'
Summary of Estimated Fair Values of Separately Identifiable Assets Acquired and Liabilities Assumed	'
	The following table summarizes the purchase price allocation that includes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of March 2, 2013:


	(in millions)
	Cash					$	0.4
	Accounts receivable (A)						6.5
	Inventory (B)						9.4
	Prepaids and other assets						2.9
	Property, plant, and equipment						0.3
	Goodwill						48.2
	Intangible assets:
	Developed technology (weighted-average useful life of 10 years)			5.9
	Customer relationships (weighted-average useful life of 10.6 years)			18.5
	Tradename (estimate useful life of 2 years)			0.9

	Total intangible assets						25.3
	Other assets						0.1

	Total assets acquired						93.1
	Accounts payable and accrued expenses						(5.4	)
	Deferred revenue (B)						(0.8	)
	Accrued warranty						(1.1	)
	Debt						(0.8	)
	Deferred taxes						(4.7	)

	Total liabilities assumed						(12.8	)

	Total purchase price					$	80.3


	(A)	The gross amount due was $8.7 million, of which $2.2 million is expected to be uncollectible. We did not acquire any other class of receivables other than trade receivables as a result of the acquisition of Ultrasonix.
	(B)	The inventory fair value adjustment of $3.7 million associated with the acquisition was fully amortized as of October 31, 2013. The deferred revenue adjustment of $0.8 million associated with the acquisition will be amortized over 4.5 years. The inventory fair value and deferred revenue adjustments were recognized in product cost of sales and product revenue in our condensed consolidated statement of operations, respectively.

Accounts_Receivable_Net_Tables

Accounts Receivable, Net (Tables)	9 Months Ended
Accounts Receivable, Net (Tables)	Apr. 30, 2014
Major Customers Who Accounted for 10% or More of net Revenue	'
	Set forth in the table below, are customers which individually accounted for 10% or more of our net revenue.


			For the Three Months Ended						For the Nine Months Ended
			April 30,						April 30,
			2014			2013			2014			2013
	Koninklijke Philips Electronics N.V., or Philips			17	%		14	%		17	%		14	%
	L-3 Communications Corporation, or L-3			12	%		13	%		11	%		12	%
	Toshiba Corporation			10	%		*			11	%		11	%
	Siemens AG			12	%		11	%		11	%		*

	Note	(*): Total net revenue was less than 10% in this period.
Summary of Net Accounts Receivable Due from Customers With Net Accounts Receivable Balance Greater than or Equal to 10% of Net Account Receivable Balance	'
	The following table summarizes the net accounts receivable due from our customers with net accounts receivable balances greater than or equal to 10% of our total net accounts receivable balance:


			As of			As of
			April 30,			July 31,
			2014			2013
	Philips			22	%		18	%
	L-3			15	%		16	%

Inventory_Tables

Inventory (Tables)	9 Months Ended
Inventory (Tables)	Apr. 30, 2014
Components of Inventory	'
	The components of inventory are summarized as follows:


	(in millions)	As of		As of
		April 30,		July 31,
		2014		2013
	Raw materials	$	58.9	$	78.7
	Work in process		36.4		11.9
	Finished goods		25.1		25.7

	Total inventory	$	120.4	$	116.3

Property_Plant_and_Equipment_N1

Property, Plant and Equipment, Net (Tables)	9 Months Ended
Property, Plant and Equipment, Net (Tables)	Apr. 30, 2014
Summary of Property, Plant, and Equipment	'
	The following table summarizes property, plant, and equipment, net:


	(in millions)	Estimated Useful Lives	As of			As of
		(Years)	April 30,			July 31,
			2014			2013
	Land and land improvements	N/A	$	7.6		$	7.4
	Building and improvements	35 to 40		85.2			83
	Leasehold and capital lease improvements	lesser of useful life or the lease term		10.7			10.7
	Manufacturing and engineering equipment	4 to 7		94.8			89.7
	Furniture, fixtures, and computer equipment	3 to 7		34.6			22.9
	Motor vehicles	3 to 5		2.3			2
	Construction in process	N/A		7			13.7
				242.2			229.4
	Less accumulated depreciation and amortization			(128.6	)		(118.4	)
	Total property, plant and equipment, net		$	113.6		$	111

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
Goodwill and Other Intangible Assets (Tables)	Apr. 30, 2014
Other Intangible Assets	'
	Other intangible assets are summarized as follows:


		As of April 30, 2014						As of July 31, 2013
	(in millions)	Cost		Accumulated		Net		Cost		Accumulated		Net
	(in millions)	Cost		Amortization		Net		Cost		Amortization		Net
	Developed technologies	$	18.1	$	8.2	$	9.9	$	18.1	$	6.6	$	11.5
	Customer relationships		44		14		30		43.9		10.2		33.7
	Backlog		2.1		2.1		-		2.1		2.1		-
	Tradenames		8.5		0.4		8.1		8.5		0.1		8.4
	In-process research and development		11.5		-		11.5		1.9		-		1.9
	Total intangible assets	$	84.2	$	24.7	$	59.5	$	74.5	$	19	$	55.5
Estimated Future Amortization Expenses Related to Intangible Assets	'
	The estimated future amortization expense related to intangible assets for each of the five succeeding fiscal years is expected to be as follows:


	(in millions)	Estimated
		future
		amortization
		expense
	2014 (remaining three months)	$	1.9
	2015		7.6
	2016		6.6
	2017		5.9
	2018		5
	Thereafter		13.3

		$	40.3

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Apr. 30, 2014
Assets and Liabilities Measured and Carried at Fair Value	'
	The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:


	(in millions)	As of		Quoted		Significant		Significant
		April 30,		Prices in		Other		Unobservable
		2014		Active		Observable		Inputs
				Markets		Inputs		(Level 3)
				(Level 1)		(Level 2)
	Assets
	Cash equivalents	$	0.6	$	-	$	0.6	$	-
	Plan assets for deferred compensation		3.5		3.5		-		-
	Total assets at fair value	$	4.1	$	3.5	$	0.6	$	-
	Liabilities
	Contingent consideration	$	2.1	$	-	$	-	$	2.1
	Total liabilities at fair value	$	2.1	$	-	$	-	$	2.1

	(in millions)	As of		Quoted		Significant		Significant
		July 31,		Prices in		Other		Unobservable
		2013		Active		Observable		Inputs
				Markets		Inputs		(Level 3)
				(Level 1)		(Level 2)
	Assets
	Cash equivalents	$	0.8	$	-	$	0.8	$	-
	Plan assets for deferred compensation		2.7		2.7		-		-
	Total assets at fair value	$	3.5	$	2.7	$	0.8	$	-
	Liabilities
	Foreign currency forward contracts	$	0.2	$	-	$	0.2	$	-
	Total liabilities at fair value	$	0.2	$	-	$	0.2	$	-
Reconciliations of Changes in Fair Value of Contingent Consideration	'
	The following table reconciles the changes in the fair value of contingent consideration obligations that are categorized as Level 3 within the fair value hierarchy:


		For the Three Months Ended		For the Nine Months Ended
		April 30,		April 30,
	(in millions)	2014		2014
	Fair value, beginning of period	$	2	$	-
	Acquisition date fair value of contingent consideration		-		1.9
	Change in fair value		0.1		0.2
	Payments		-		-
	Fair value, end of period	$	2.1	$	2.1

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
Accumulated Other Comprehensive Income (Tables)	Apr. 30, 2014
Changes in Accumulated Other Comprehensive Income	'
	The following table summarizes components of accumulated other comprehensive income for the nine months ended April 30, 2013:


	(in millions)	Unrealized			Unrealized			Currency		Accumulated
		Gains			Gains			Translation		Other
		(Losses) on			(Losses) on					Comprehensive
		Foreign			Pension Plan					Income
		Currency
		Forward
		Contracts
	Balance as of July 31, 2012	$	-		$	(4.7	)	$	7	$	2.3
	Pre-tax change before reclass to earnings		(0.1	)		-			4		3.9
	Amount reclassed to earnings (Note 9)		0.1			-			-		0.1
	Income tax benefit		-			-			0.3		0.3
	Balance as of April 30, 2013	$	-		$	(4.7	)	$	11.3	$	6.6
	The following table summarizes components of accumulated other comprehensive income for the nine months ended April 30, 2014:


	(in millions)	Unrealized			Unrealized			Currency		Accumulated
		Gains			Gains			Translation		Other
		(Losses) on			(Losses) on					Comprehensive
		Foreign			Pension Plan					Income
		Currency
		Forward
		Contracts
	Balance as of July 31, 2013	$	(0.1	)	$	(2.3	)	$	11.5	$	9.1
	Pre-tax change before reclass to earnings		-			-			1.4		1.4
	Amount reclassed to earnings (Note 9)		0.2			-			-		0.2
	Income tax benefit		-			-			0.1		0.1
	Balance as of April 30, 2014	$	0.1		$	(2.3	)	$	13	$	10.8

Sharebased_Compensation_Tables

Share-based Compensation (Tables)	9 Months Ended
Share-based Compensation (Tables)	Apr. 30, 2014
Share-Based Compensation Expenses for Continuing Operations	'
	The following table presents share-based compensation expense included in our condensed consolidated statements of operations:


			For the Three Months Ended						For the Nine Months Ended
			April 30,						April 30,
	(in millions)		2014			2013			2014			2013
	Cost of product sales		$	0.1		$	0.2		$	0.5		$	0.6
	Cost of engineering sales			0.1			0.2			0.3			0.9
	Research and product development			0.5			0.3			2			1.5
	Selling and marketing			0.3			0.2			0.9			0.7
	General and administrative			1.9			1.1			5			4.3
	Total share-based compensation expense before tax			2.9			2			8.7			8
	Income tax effect			(0.9	)		(0.5	)		(2.7	)		(2.5	)
	Share-based compensation expense included in net income		$	2		$	1.5			6		$	5.5
Fair Value of Option Grant Assumptions	'
	The fair value of each option granted during the three and nine months ended April 30, 2014 and 2013 was estimated on the grant date using the Black-Scholes valuation model with the following assumptions:


			For the Three Months Ended						For the Nine Months Ended
			April 30,						April 30,
			2014			2013			2014			2013
	Expected option term in years (1)			5.31			5.47			5.37			5.42
	Expected volatility (2)			35.1	%		41	%		38.6	%		41	%
	Risk-free interest rate (3)			1.51	%		0.91	%		1.77	%		0.8	%
	Expected annual dividend yield (4)			0.42	%		0.52	%		0.52	%		0.57	%

	-1	The expected option term was estimated using historical data.
	-2	The expected volatility for each grant is determined based on the review of the average of historical daily price changes of our common stock over the expected option term.
	-3	The risk-free interest rate is determined based on the yield of zero-coupon U.S. Treasury securities for a period that is commensurate with the expected term assumption.
	-4	The expected annual dividend yield is calculated by dividing the expected annual dividends by the stock price on the date of grant.
Fair Value of Awards Grant Assumptions	'
	The fair value of our TSR performance-based awards at the date of grant was estimated using the Monte-Carlo simulation model with the following assumptions:


			For the Three Months Ended						For the Nine Months Ended
			April 30,						April 30,
			2014			2013			2014			2013
	Stock Price (1)		$	94.32		$	70.04		$	77.14		$	70.04
	Expected volatility (2)			27.5	%		28	%		27.6	%		28	%
	Risk-free interest rate (3)			0.46	%		0.32	%		0.82	%		0.32	%
	Expected annual dividend yield (4)			0	%		0	%		0	%		0	%

	-1	The stock price is the closing price of our common stock on the date of grant.
	-2	The expected volatility for each grant is determined based on the historical volatility for the peer group companies and our common stock over a period equal to the remaining term of the performance period from the date of grant for all awards.
	-3	The risk free interest rate is determined based on the yield of zero-coupon U.S. Treasury securities for a period that is commensurate with the performance period.
	-4	Dividends are considered reinvested when calculating TSR. The dividend yield is therefore considered to be 0%.

Restructuring_Charges_Tables

Restructuring Charges (Tables)	9 Months Ended
Restructuring Charges (Tables)	Apr. 30, 2014
Summary of Accrued Restructuring Costs Activity	'
	The following table summarizes charges related to the accrued restructuring activities during the three and nine months ended April 30, 2014.


	(in millions)	Employee			Facility			Acquisition			Total
		Severance			Exit			Related
		and Benefits			Costs			Charges
	Balance at July 31, 2013	$	1.8		$	0.2		$	0.8		$	2.8
	Restructuring charge		0.2			-			0.1			0.3
	Adjustments		(0.2	)		-			(0.1	)		(0.3	)
	Cash payments		(0.5	)		-			(0.1	)		(0.6	)
	Currency translation		-			-			-			-
	Balance at October 31, 2013	$	1.3		$	0.2		$	0.7		$	2.2
	Restructuring charge		-			0.6			-			0.6
	Adjustments		(0.2	)		(0.1	)		-			(0.3	)
	Cash payments		(0.6	)		-			(0.4	)		(1.0	)
	Currency translation		-			-			-			-
	Balance at January 31, 2014	$	0.5		$	0.7		$	0.3		$	1.5
	Restructuring charge		-			-			0.1			0.1
	Adjustments		-			-			(0.2	)		(0.2	)
	Cash payments		(0.3	)		(0.1	)		(0.1	)		(0.5	)
	Currency translation		-			-			-			-
	Balance at April 30, 2014	$	0.2		$	0.6		$	0.1		$	0.9
	The following table summarizes charges related to the accrued restructuring activities during the nine months ended April 30, 2013.


	(in millions)	Employee			Facility			Acquisition			Total
		Severance			Exit			Related
		and Benefits			Costs			Charges
	Balance at July 31, 2012	$	-		$	-		$	-		$	-
	Restructuring charge		0.1			-			0.4			0.5
	Adjustments		-			-			-			-
	Cash payments		-			-			-			-
	Currency translation		-			-			-			-
	Balance at April 30, 2013	$	0.1		$	-		$	0.4		$	0.5
Restructuring and Related Charges	'
	Restructuring and related charges, including actions associated with acquisitions, by segment are as follows:


		For the Three Months Ended						For the Nine Months Ended
		April 30,						April 30,
	(in millions)	2014			2013			2014			2013
	Medical Imaging	$	-		$	0.1		$	(0.2	)	$	0.1
	Ultrasound		(0.1	)		0.4			0.4			0.4
	Security Technology		-			-			-			-
	Total restructuring and related charges	$	(0.1	)	$	0.5		$	0.2		$	0.5

Net_Income_Per_Common_Share_Ta

Net Income Per Common Share (Tables)	9 Months Ended
Net Income Per Common Share (Tables)	Apr. 30, 2014
Computation of Basic and Diluted Net Income Per Share	'
	Basic and diluted net income per share are calculated as follows:


		For the Three Months Ended				For the Nine Months Ended
		April 30,				April 30,
	(in millions)	2014		2013		2014		2013
	Net income	$	7.8	$	5.2	$	23.3	$	19.4

	Weighted-average number of common shares outstanding-basic (000’s)		12,403		12,305		12,421		12,300
	Effect of dilutive securities:
	Stock options and restricted stock units (000’s)		244		315		258		284
	Weighted-average number of common shares outstanding-diluted (000’s)	$	12,647	$	12,620	$	12,679	$	12,584

	Basic net income per share:	$	0.63	$	0.42	$	1.88	$	1.58
	Diluted net income per share:	$	0.62	$	0.41	$	1.84	$	1.54

Income_Taxes_Tables

Income Taxes (Tables)	9 Months Ended
Income Taxes (Tables)	Apr. 30, 2014
Provision for (Benefit from) Income Taxes and Effective Tax Rate	'
	The following table presents the provision for (benefit from) income taxes and our effective tax rate for the three and nine months ended April 30, 2014 and 2013:


		For the Three Months Ended						For the Nine Months Ended
		April 30,						April 30,
	(in millions)	2014			2013			2014			2013
	Provision for (benefit from) income taxes	$	2.5		$	1.7		$	(6.1	)	$	7.4
	Effective tax rate		24	%		24	%		-35	%		28	%
Gross Unrecognized Tax Benefits	'
	The total amounts of gross unrecognized tax benefits, which excludes interest and penalties discussed below, as of April 30, 2014 and July 31, 2013 were as follows:


	(in millions)	April 30, 2014			July 31, 2013
	Gross unrecognized tax benefits	$	6.6		$	7.3

Segment_Information_Tables

Segment Information (Tables)	9 Months Ended
Segment Information (Tables)	Apr. 30, 2014
Reportable Segment Information	'
	The tables below present information about our reportable segments:


			For the Three Months Ended						For the Nine Months Ended
			April 30,						April 30,
	(in millions)		2014			2013			2014			2013
	Product revenue:
	Medical Imaging		$	70.7		$	68.8		$	208.3		$	218.5
	Ultrasound			37.3			33.9			112.1			106
	Security Technology			14.1			18.5			49.6			42
	Total product revenue		$	122.1		$	121.2		$	370		$	366.5
	Engineering revenue:
	Medical Imaging		$	1		$	2.9		$	3.2		$	9.9
	Ultrasound			-			0.1			-			0.1
	Security Technology			1			1.6			2.4			7.7
	Total engineering revenue		$	2		$	4.6		$	5.6		$	17.7
	Net revenue:
	Medical Imaging		$	71.7		$	71.7		$	211.5		$	228.4
	Ultrasound			37.3			34			112.1			106.1
	Security Technology			15.1			20.1			52			49.7
	Total net revenue		$	124.1		$	125.8		$	375.6		$	384.2
	Income from operations:
	Medical Imaging		$	8.9		$	6.5		$	19.3		$	22.4
	Ultrasound			(1.3	)		(4.4	)		(6.1	)		(1.7	)
	Security Technology			1.8			4.6			3.9			7.2
	Total income from operations			9.4			6.7			17.1			27.9
	Total other income (expenses), net			0.9			0.2			0.1			(1.1	)
	Income before income taxes		$	10.3		$	6.9		$	17.2		$	26.8


			As of			As of
			April 30,			July 31,
	(in millions)		2014			2013
	Identifiable assets by segment:
	Medical Imaging		$	215.8		$	217.1
	Ultrasound			221.7			218.4
	Security Technology			32.9			53.4
	Total reportable segment assets			470.4			488.9
	Corporate assets (A)			132			98.9
	Total assets		$	602.4		$	587.8


			As of			As of
			April 30,			July 31,
	(in millions)		2014			2013
	Goodwill by segment:
	Medical Imaging		$	1.9		$	1.9
	Ultrasound			48.2			48.2
	Security Technology			-			-
	Corporate (B)			6.9			-
	Total goodwill		$	57		$	50.1

	(A)	Includes cash and cash equivalents of $73.5 million and $57.4 million as of April 30, 2014 and July 31, 2013, respectively.
	(B)	Includes goodwill related to the acquisition of PocketSonics. Please see Note 7. Goodwill and Other Intangible Assets for further discussion on PocketSonics.

Guarantees_Commitments_and_Con1

Guarantees, Commitments and Contingencies (Tables)	9 Months Ended
Guarantees, Commitments and Contingencies (Tables)	Apr. 30, 2014
Product Warranty Liability	'
	The following table presents our product warranty liability for the nine months ended April 30, 2014 and the twelve months ended July 31, 2013:


	(in millions)	As of			As of
		April 30,			July 31,
		2014			2013
	Product warranty liability, beginning balance	$	6.5		$	5.6
	Provision
	Provision		3.1			5.3
	Ultrasonix warranty accrual acquired		-			1.2
	Settlements made in cash or in kind during the period		(3.4	)		(5.6	)
	Product warranty liability, ending balance	$	6.2		$	6.5

Leases_and_Other_Commitments_T

Leases and Other Commitments (Tables)	9 Months Ended
Leases and Other Commitments (Tables)	Apr. 30, 2014
Future Minimum Lease Payments	'
	The following is a schedule by year of future minimum lease payments at April 30, 2014:


	(in millions)	Future Minimum Lease
	Fiscal Year	Payments
	2014 (3 months)	$	0.8
	2015		2.1
	2016		1.3
	2017		0.9
	2018		0.7
	Thereafter		1.2

		$	7

Business_Additional_Informatio

Business - Additional Information (Detail)	9 Months Ended
	Apr. 30, 2014
	Segment
Organization and Summary of Significant Accounting Policies Disclosure [Line Items]	'
Number Of Operating Segments	3
Minimum	'
Organization and Summary of Significant Accounting Policies Disclosure [Line Items]	'
Ownership interests	10.00%
Maximum	'
Organization and Summary of Significant Accounting Policies Disclosure [Line Items]	'
Ownership interests	50.00%

Business_Combination_Additiona

Business Combination - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Apr. 30, 2013

Jul. 31, 2013

Apr. 30, 2014

Sep. 20, 2013

Apr. 30, 2014

Oct. 31, 2013

Apr. 30, 2014

Apr. 30, 2010

Sep. 20, 2013

Apr. 30, 2014

Sep. 20, 2013

Apr. 30, 2010

Apr. 30, 2014

Mar. 02, 2013

Apr. 30, 2014

Oct. 31, 2013

Minimum

Maximum

In-process research and development

PocketSonics

Ultrasonix

Minimum

Maximum

In-process research and development

General and Administrative

Cost of product sales

Minimum

Maximum

Business Acquisition [Line Items]

Ownership interests

10.00%

50.00%

10.00%

Amount of equity investment

$1,900,000

Amount merger consideration paid

11,100,000

Contingent consideration

1,900,000

2,100,000

3,000,000

Intangible assets

11,500,000

25,300,000

Amortization period

'10 years

Production period

'3 months

'6 months

'3 months

'6 months

Increases in contingent consideration

183,000

-120,000

100,000

200,000

Business acquisition, goodwill

56,955,000

50,073,000

6,900,000

2,800,000

48,200,000

Loss from pre-acquisition equity interest

500,000

Acquisition related charges

100,000

1,900,000

6,200,000

Purchase price, net of cash acquired

10,561,000

79,273,000

79,900,000

Amortization expense related to acquired intangible assets

1,900,000

1,200,000

5,700,000

2,700,000

5,700,000

Inventory step up charge

$500,000

Summary_of_Estimated_Fair_Valu

Summary of Estimated Fair Values of Separately Identifiable Assets Acquired and Liabilities Assumed (Detail) (USD $)	Apr. 30, 2014	Jul. 31, 2013	Mar. 02, 2013		Mar. 02, 2013	Mar. 02, 2013	Mar. 02, 2013	Apr. 30, 2014	Sep. 20, 2013	Sep. 20, 2013
			Ultrasonix		Ultrasonix	Ultrasonix	Ultrasonix	PocketSonics	PocketSonics	PocketSonics
					Developed technologies	Customer relationships	Tradenames			In-process research and development
Business Acquisition [Line Items]	'	'	'		'	'	'	'	'	'
Cash	'	'	$400,000		'	'	'	'	$500,000	'
Goodwill	56,955,000	50,073,000	48,200,000		'	'	'	2,800,000	6,900,000	'
Intangible assets	'	'	25,300,000		5,900,000	18,500,000	900,000	'	'	11,500,000
Total assets acquired	'	'	93,100,000		'	'	'	'	18,900,000	'
Accounts payable and accrued expenses	'	'	-5,400,000		'	'	'	'	-300,000	'
Deferred taxes	'	'	-4,700,000		'	'	'	'	-4,100,000	'
Total liabilities assumed	'	'	-12,800,000		'	'	'	'	-4,400,000	'
Total purchase price	'	'	80,300,000		'	'	'	'	14,500,000	'
Accounts receivable	'	'	6,500,000	[1]	'	'	'	'	'	'
Inventory	'	'	9,400,000	[2]	'	'	'	'	'	'
Prepaids and other assets	'	'	2,900,000		'	'	'	'	'	'
Property, plant, and equipment	'	'	300,000		'	'	'	'	'	'
Other assets	'	'	100,000		'	'	'	'	'	'
Deferred revenue	'	'	-800,000	[2]	'	'	'	'	'	'
Accrued warranty	'	'	-1,100,000		'	'	'	'	'	'
Debt	'	'	($800,000)		'	'	'	'	'	'

[1]	The gross amount due was $8.7 million, of which $2.2 million is expected to be uncollectible. We did not acquire any other class of receivables other than trade receivables as a result of the acquisition of Ultrasonix.
[2]	The inventory fair value adjustment of $3.7 million associated with the acquisition was fully amortized as of October 31, 2013. The deferred revenue adjustment of $0.8 million associated with the acquisition will be amortized over 4.5 years. The inventory fair value and deferred revenue adjustments were recognized in product cost of sales and product revenue in our condensed consolidated statement of operations, respectively.

Summary_of_Estimated_Fair_Valu1

Summary of Estimated Fair Values of Separately Identifiable Assets Acquired and Liabilities Assumed (Parenthetical) (Detail) (Ultrasonix, USD $)	1 Months Ended
In Millions, unless otherwise specified	Mar. 02, 2013
Business Acquisition [Line Items]	'
Gross amounts due under contracts	8.7
Contract receivable expected uncollectible	2.2
Developed technologies	'
Business Acquisition [Line Items]	'
Weighted average useful life	'10 years
Customer relationships	'
Business Acquisition [Line Items]	'
Weighted average useful life	'10 years 7 months 6 days
Tradenames	'
Business Acquisition [Line Items]	'
Weighted average useful life	'2 years
Inventories	'
Business Acquisition [Line Items]	'
Assets fair value adjustments	3.7
Deferred Revenue	'
Business Acquisition [Line Items]	'
Assets fair value adjustments	0.8
Amortization period	'4 years 6 months

Pro_Forma_Information_of_Compa

Pro Forma Information of Company as of Business Combination (Detail) (Ultrasonix, USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Ultrasonix	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'
Net revenue	$124	$128.90	$375.60	$407.70
Net income	$7.80	$4.80	$22.70	$19.40
Net income per share, basic	$0.63	$0.39	$1.83	$1.58
Net income per share, diluted	$0.62	$0.38	$1.79	$1.54

Accounts_Receivable_Net_Additi

Accounts Receivable, Net - Additional Information (Detail) (Revenue, Ten largest customers)	3 Months Ended		9 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Revenue \| Ten largest customers	'	'	'	'
Accounts Receivable [Line Items]	'	'	'	'
Percentage of total net revenue	68.00%	67.00%	67.00%	68.00%

Major_Customers_Who_Accounted_

Major Customers Who Accounted for 10% or More of Net Product and Engineering Revenue (Detail) (Total Net Revenue)	3 Months Ended			9 Months Ended
	Apr. 30, 2014	Apr. 30, 2013		Apr. 30, 2014	Apr. 30, 2013
Philips	'	'		'	'
Concentration Risk [Line Items]	'	'		'	'
Percentage of net product and engineering revenue	17.00%	14.00%		17.00%	14.00%
L-3	'	'		'	'
Concentration Risk [Line Items]	'	'		'	'
Percentage of net product and engineering revenue	12.00%	13.00%		11.00%	12.00%
Toshiba	'	'		'	'
Concentration Risk [Line Items]	'	'		'	'
Percentage of net product and engineering revenue	10.00%	'	[1]	11.00%	11.00%
Siemens AG	'	'		'	'
Concentration Risk [Line Items]	'	'		'	'
Percentage of net product and engineering revenue	12.00%	11.00%		11.00%	'	[1]

[1]	Total net revenue was less than 10% in this period.

Major_Customers_Who_Accounted_1

Major Customers Who Accounted for 10% or More of Net Product and Engineering Revenue (Parenthetical) (Detail) (Maximum)	3 Months Ended	9 Months Ended
	Apr. 30, 2013	Apr. 30, 2013
	Toshiba	Siemens AG
Concentration Risk [Line Items]	'	'
Percentage of net product and engineering revenue	10.00%	10.00%

Summary_of_Net_Accounts_Receiv

Summary of Net Accounts Receivable Due from Customers Accounted for 10% or More Account Receivable (Detail) (Net Accounts Receivable)	9 Months Ended	12 Months Ended
	Apr. 30, 2014	Jul. 31, 2013
Philips	'	'
Accounts Receivable [Line Items]	'	'
Percentage of net accounts receivable	22.00%	18.00%
L-3	'	'
Accounts Receivable [Line Items]	'	'
Percentage of net accounts receivable	15.00%	16.00%

Components_of_Inventory_Detail

Components of Inventory (Detail) (USD $)	Apr. 30, 2014	Jul. 31, 2013
Inventory [Line Items]	'	'
Raw materials	$58,900,000	$78,700,000
Work in process	36,400,000	11,900,000
Finished goods	25,100,000	25,700,000
Total inventory	$120,423,000	$116,280,000

Property_Plant_and_Equipment_D

Property, Plant, and Equipment (Detail) (USD $)	Apr. 30, 2014	Jul. 31, 2013	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2014
			Building And Improvement	Building And Improvement	Leasehold and Capital Lease Improvements	Manufacturing and Engineering Equipment	Manufacturing and Engineering Equipment	Furniture, Fixtures and Computer Equipment	Furniture, Fixtures and Computer Equipment	Motor Vehicles	Motor Vehicles
			Minimum	Maximum		Minimum	Maximum	Minimum	Maximum	Minimum	Maximum
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Property, plant and equipment estimated useful lives	'	'	'35 years	'40 years	'	'4 years	'7 years	'3 years	'7 years	'3 years	'5 years
Property, plant and equipment estimated useful lives	'	'	'	'	'lesser of useful life or the lease term	'	'	'	'	'	'
Land and land improvements	$7,600,000	$7,400,000	'	'	'	'	'	'	'	'	'
Building and improvements	85,200,000	83,000,000	'	'	'	'	'	'	'	'	'
Leasehold and capital lease improvements	10,700,000	10,700,000	'	'	'	'	'	'	'	'	'
Manufacturing and engineering equipment	94,800,000	89,700,000	'	'	'	'	'	'	'	'	'
Furniture, fixtures, and computer equipment	34,600,000	22,900,000	'	'	'	'	'	'	'	'	'
Motor vehicles	2,300,000	2,000,000	'	'	'	'	'	'	'	'	'
Construction in process	7,000,000	13,700,000	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment, Gross, Total	242,200,000	229,400,000	'	'	'	'	'	'	'	'	'
Less accumulated depreciation and amortization	-128,600,000	-118,400,000	'	'	'	'	'	'	'	'	'
Total property, plant and equipment, net	$113,622,000	$110,983,000	'	'	'	'	'	'	'	'	'

Property_Plant_and_Equipment_N2

Property, Plant and Equipment, Net - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Property, Plant, and Equipment Disclosure [Line Items]	'	'	'	'
Depreciation of property, plant, and equipment	$3.50	$3.30	$10.60	$9.70

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Apr. 30, 2013

Jul. 31, 2013

Apr. 30, 2014

Sep. 20, 2013

Apr. 30, 2014

PocketSonics

Copley Controls

Ultrasonix and PocketSonics

Minimum

Maximum

In-process research and development

PocketSonics

Minimum

Maximum

PocketSonics

Goodwill and Intangible Assets Disclosure [Line Items]

Goodwill

$56,955,000

$50,073,000

$2,800,000

$6,900,000

Acquisition of goodwill

6,900,000

1,800,000

55,200,000

Business acquisition, additional increase in goodwill

4,100,000

Intangible assets, estimated useful lives

'1 year

'14 years

Amortization expense related to acquired intangible assets

$1,900,000

$1,200,000

$5,700,000

$2,700,000

Production period

'3 months

'6 months

Other_Intangible_Assets_Detail

Other Intangible Assets (Detail) (USD $)	Apr. 30, 2014	Jul. 31, 2013
In Millions, unless otherwise specified	Apr. 30, 2014	Jul. 31, 2013
Intangible Assets by Major Class [Line Items]	'	'
Cost	$84.20	$74.50
Accumulated Amortization	24.7	19
Net	59.5	55.5
Developed technologies	'	'
Intangible Assets by Major Class [Line Items]	'	'
Cost	18.1	18.1
Accumulated Amortization	8.2	6.6
Net	9.9	11.5
Customer relationships	'	'
Intangible Assets by Major Class [Line Items]	'	'
Cost	44	43.9
Accumulated Amortization	14	10.2
Net	30	33.7
Backlog	'	'
Intangible Assets by Major Class [Line Items]	'	'
Cost	2.1	2.1
Accumulated Amortization	2.1	2.1
Tradenames	'	'
Intangible Assets by Major Class [Line Items]	'	'
Cost	8.5	8.5
Accumulated Amortization	0.4	0.1
Net	8.1	8.4
In-process research and development	'	'
Intangible Assets by Major Class [Line Items]	'	'
Cost	11.5	1.9
Net	$11.50	$1.90

Estimated_Future_Amortization_

Estimated Future Amortization Expense Related to Intangible Assets (Detail) (USD $)	Apr. 30, 2014
In Millions, unless otherwise specified	Apr. 30, 2014
Finite Lived Intangible Assets Future Amortization Expense [Line Items]	'
2014 (remaining three months)	$1.90
2015	7.6
2016	6.6
2017	5.9
2018	5
Thereafter	13.3
Finite-Lived Intangible Assets, Amortization Expense, Total	$40.30

Assets_and_Liabilities_Carried

Assets and Liabilities Carried at Fair Value Measured on Recurring Basis (Detail) (Fair Value, Measurements, Recurring, USD $)	Apr. 30, 2014	Jul. 31, 2013
In Millions, unless otherwise specified	Apr. 30, 2014	Jul. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	$0.60	$0.80
Plan assets for deferred compensation	3.5	2.7
Total assets at fair value	4.1	3.5
Contingent consideration	2.1	'
Foreign currency forward contracts	'	0.2
Total liabilities at fair value	2.1	0.2
Quoted Prices in Active Markets (Level 1)	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Plan assets for deferred compensation	3.5	2.7
Total assets at fair value	3.5	2.7
Significant Other Observable Inputs (Level 2)	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	0.6	0.8
Total assets at fair value	0.6	0.8
Foreign currency forward contracts	'	0.2
Total liabilities at fair value	'	0.2
Significant Unobservable Inputs (Level 3)	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Contingent consideration	2.1	'
Total liabilities at fair value	$2.10	'

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of contingent payments, percentage of volume sales target	27.00%
Equity investment, carrying value	$0

Reconciliations_of_Changes_in_

Reconciliations of Changes in Fair Value of Contingent Consideration (Detail) (Significant Unobservable Inputs (Level 3), USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2014
Significant Unobservable Inputs (Level 3)	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning Balance	$2	'
Acquisition date fair value of contingent consideration	'	1.9
Change in fair value	0.1	0.2
Payments	'	'
Ending Balance	$2.10	$2.10

Derivative_Instruments_Additio

Derivative Instruments - Additional Information (Detail) (Forward contracts)	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
In Millions, unless otherwise specified	CAD	Maximum	Cost of Revenue and Operating Expenses	Cost of Revenue and Operating Expenses	Cost of Revenue and Operating Expenses	Cost of Revenue and Operating Expenses
		USD ($)	USD ($)	USD ($)	USD ($)	USD ($)
Derivative [Line Items]	'	'	'	'	'	'
Notional amount of cash flow hedge instruments	3	'	'	'	'	'
Unrealized loss on cash flow hedges	'	-0.1	'	'	'	'
Realized gains (losses) on cash flow hedge instruments	'	'	$0.10	($0.10)	($0.20)	$0.10

Common_Stock_Repurchases_Addit

Common Stock Repurchases - Additional Information (Detail) (Stock Repurchase Plan Two, USD $)	1 Months Ended	3 Months Ended		9 Months Ended		1 Months Ended
In Millions, except Share data, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	Dec. 08, 2011
	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	Maximum
Stockholders Equity Note [Line Items]	'	'	'	'	'	'
Amount authorized for repurchase of Company's common stock	'	'	'	'	'	$30
Repurchase of common stock (in shares)	375,335	43,740	0	125,928	85,327	'
Repurchase of common stock	$27	$3.60	$0	$10.60	$6	'
Average purchase price of common stock	$71.86	$82.65	$0	$83.98	$70.56	'

Changes_in_Accumulated_Other_C

Changes in Accumulated Other Comprehensive Income (Detail) (USD $)	9 Months Ended								9 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Jul. 31, 2013	Apr. 30, 2013	Jul. 31, 2012	Apr. 30, 2014	Apr. 30, 2013
	Apr. 30, 2014	Apr. 30, 2013	Unrealized Gains (Losses) on Foreign Currency Forward Contracts	Unrealized Gains (Losses) on Foreign Currency Forward Contracts	Unrealized Gains (Losses) on Pension Plan	Unrealized Gains (Losses) on Pension Plan	Unrealized Gains (Losses) on Pension Plan	Unrealized Gains (Losses) on Pension Plan	Currency Translation	Currency Translation
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'	'	'	'	'	'	'
Accumulated Other Comprehensive Income,Net of Tax, Beginning balance	$9,148,000	$2,300,000	($100,000)	'	($2,300,000)	($2,300,000)	($4,700,000)	($4,700,000)	$11,500,000	$7,000,000
Pre-tax change before reclass to earnings	1,400,000	3,900,000	'	-100,000	'	'	'	'	1,400,000	4,000,000
Amount reclassed to earnings (Note 9)	200,000	100,000	200,000	100,000	'	'	'	'	'	'
Income tax benefit	100,000	300,000	'	'	'	'	'	'	100,000	300,000
Accumulated Other Comprehensive Income, Net of Tax, Ending balance	$10,775,000	$6,600,000	$100,000	'	($2,300,000)	($2,300,000)	($4,700,000)	($4,700,000)	$13,000,000	$11,300,000

Sharebased_Compensation_Additi

Share-based Compensation - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

6 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Apr. 30, 2014

Nov. 04, 1985

Jan. 21, 2014

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Jan. 21, 2014

Jan. 23, 2012

Jan. 29, 2010

Apr. 30, 2014

Employee Stock Purchase Plan

Stock Options

Total Shareholders Return

Non-GAAP EPS Performance-Based Awards

Time Based Restricted Stock Awards

Performance Based Restricted Stock Awards

2009 Stock Incentive Plan

Stock Option and Restricted Stock Bonus Plans

Before Amendment

After Amendment

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common stock shares authorized to be granted

700,000

4,453,518

2,200,000

1,600,000

Maximum value of stock per employees can purchase

$2,600

$12,500

Weighted average grant date fair value of awards granted

$30.80

$27.90

$27.55

$25.25

$95.49

$82.46

$117.61

$93.85

Intrinsic value of options exercised

100,000

1,700,000

Stock options vested or expected to vest, shares

402,950

Stock options exercisable, shares

177,567

Stock options vested or expected to vest, weighted average exercise price

$63.34

Stock options exercisable, weighted average exercise price

$55.67

Stock options vested or expected to vest, aggregate intrinsic value

5,000,000

Stock options exercisable, aggregate intrinsic value

3,500,000

Stock options vested or expected to vest, weighted average remaining contractual term

'5 years 1 month 13 days

Stock options exercisable, weighted average remaining contractual term

'4 years 1 month 6 days

Options, grants in period

413

124

537

Total fair value of restricted stock grants vested in period

700,000

20,800,000

Unrecognized compensation cost related to non-vested share-based compensation arrangements

$13,400,000

Unrecognized compensation cost related to non-vested share-based compensation arrangements, weighted average period

'1 year 6 months

Sharebased_Compensation_Expens

Share-based Compensation Expenses (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Compensation Related Costs Share Based Payments Disclosure [Line Items]	'	'	'	'
Share-based compensation expense before tax	$2.90	$2	$8.70	$8
Income tax effect	-0.9	-0.5	-2.7	-2.5
Share-based compensation expense included in net income	2	1.5	6	5.5
Cost of product sales	'	'	'	'
Compensation Related Costs Share Based Payments Disclosure [Line Items]	'	'	'	'
Share-based compensation expense before tax	0.1	0.2	0.5	0.6
Cost of Engineering Sales	'	'	'	'
Compensation Related Costs Share Based Payments Disclosure [Line Items]	'	'	'	'
Share-based compensation expense before tax	0.1	0.2	0.3	0.9
Research and Product Development	'	'	'	'
Compensation Related Costs Share Based Payments Disclosure [Line Items]	'	'	'	'
Share-based compensation expense before tax	0.5	0.3	2	1.5
Selling and Marketing	'	'	'	'
Compensation Related Costs Share Based Payments Disclosure [Line Items]	'	'	'	'
Share-based compensation expense before tax	0.3	0.2	0.9	0.7
General and Administrative	'	'	'	'
Compensation Related Costs Share Based Payments Disclosure [Line Items]	'	'	'	'
Share-based compensation expense before tax	$1.90	$1.10	$5	$4.30

Fair_Value_of_Option_Grant_Ass

Fair Value of Option Grant Assumptions (Detail) (USD $)	3 Months Ended				9 Months Ended
Fair Value of Option Grant Assumptions (Detail) (USD $)	Apr. 30, 2014		Apr. 30, 2013		Apr. 30, 2014		Apr. 30, 2013
Stock Options	'		'		'		'
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]	'		'		'		'
Expected option term in years	'5 years 3 months 22 days	[1]	'5 years 5 months 19 days	[1]	'5 years 4 months 13 days	[1]	'5 years 5 months 1 day	[1]
Expected volatility	35.10%	[2]	41.00%	[2]	38.60%	[2]	41.00%	[2]
Risk-free interest rate	1.51%	[3]	0.91%	[3]	1.77%	[3]	0.80%	[3]
Expected annual dividend yield	0.42%	[4]	0.52%	[4]	0.52%	[4]	0.57%	[4]
Total Shareholders Return	'		'		'		'
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]	'		'		'		'
Stock Price	94.32	[5]	70.04	[5]	77.14	[5]	70.04	[5]
Expected volatility	27.50%	[6]	28.00%	[6]	27.60%	[6]	28.00%	[6]
Risk-free interest rate	0.46%	[7]	0.32%	[7]	0.82%	[7]	0.32%	[7]
Expected annual dividend yield	0.00%	[8]	0.00%	[8]	0.00%	[8]	0.00%	[8]

[1]	The expected option term was estimated using historical data.
[2]	The expected volatility for each grant is determined based on the review of the average of historical daily price changes of our common stock over the expected option term.
[3]	The risk-free interest rate is determined based on the yield of zero-coupon U.S. Treasury securities for a period that is commensurate with the expected term assumption.
[4]	The expected annual dividend yield is calculated by dividing the expected annual dividends by the stock price on the date of grant.
[5]	The stock price is the closing price of our common stock on the date of grant.
[6]	The expected volatility for each grant is determined based on the historical volatility for the peer group companies and our common stock over a period equal to the remaining term of the performance period from the date of grant for all awards.
[7]	The risk free interest rate is determined based on the yield of zero-coupon U.S. Treasury securities for a period that is commensurate with the performance period.
[8]	Dividends are considered reinvested when calculating TSR. The dividend yield is therefore considered to be 0%.

Fair_Value_of_Option_Grant_Ass1

Fair Value of Option Grant Assumptions (Parenthetical) (Detail) (Total Shareholders Return)	3 Months Ended				9 Months Ended
	Apr. 30, 2014		Apr. 30, 2013		Apr. 30, 2014		Apr. 30, 2013
Total Shareholders Return	'		'		'		'
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]	'		'		'		'
Expected annual dividend yield	0.00%	[1]	0.00%	[1]	0.00%	[1]	0.00%	[1]

[1]	Dividends are considered reinvested when calculating TSR. The dividend yield is therefore considered to be 0%.

Restructuring_Charges_Addition

Restructuring Charges - Additional Information (Detail) (USD $)	3 Months Ended			6 Months Ended	9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013	Jan. 31, 2013	Jan. 31, 2013	Apr. 30, 2014	Apr. 30, 2013	Jul. 31, 2013
							Ultrasonix
							Employee
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'
Involuntarily terminated employees	'	'	'	'	'	'	115
Restructuring charges	($80)	$496	$0	$0	$216	$496	'

Summary_of_Charges_Related_to_

Summary of Charges Related to Accrued Restructuring Activity (Detail) (USD $)	3 Months Ended			9 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2014	Jan. 31, 2014	Oct. 31, 2013	Apr. 30, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Balance at beginning period	$1.50	$2.20	$2.80	'
Restructuring charge	0.1	0.6	0.3	0.5
Adjustments	-0.2	-0.3	-0.3	'
Cash payments	-0.5	-1	-0.6	'
Currency translation	'	'	'	'
Balance at end period	0.9	1.5	2.2	0.5
Employee Severance and Benefits	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Balance at beginning period	0.5	1.3	1.8	'
Restructuring charge	'	'	0.2	0.1
Adjustments	'	-0.2	-0.2	'
Cash payments	-0.3	-0.6	-0.5	'
Currency translation	'	'	'	'
Balance at end period	0.2	0.5	1.3	0.1
Facility Exit Costs	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Balance at beginning period	0.7	0.2	0.2	'
Restructuring charge	'	0.6	'	'
Adjustments	'	-0.1	'	'
Cash payments	-0.1	'	'	'
Currency translation	'	'	'	'
Balance at end period	0.6	0.7	0.2	'
Aquisition Related Charges	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Balance at beginning period	0.3	0.7	0.8	'
Restructuring charge	0.1	'	0.1	0.4
Adjustments	-0.2	'	-0.1	'
Cash payments	-0.1	-0.4	-0.1	'
Currency translation	'	'	'	'
Balance at end period	$0.10	$0.30	$0.70	$0.40

Restructuring_and_Related_Char

Restructuring and Related Charges by Segment (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring and related charges, net	($0.10)	$0.50	$0.20	$0.50
Medical Imaging	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring and related charges, net	'	0.1	-0.2	0.1
Ultrasound	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring and related charges, net	($0.10)	$0.40	$0.40	$0.40

Computation_of_Basic_and_Dilut

Computation of Basic and Diluted Net Income Per Share (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Schedule of Earnings Per Share, Basic and Diluted, by Common Class [Line Items]	'	'	'	'
Net income	$7,790	$5,224	$23,329	$19,414
Weighted-average number of common shares outstanding-basic	12,403	12,305	12,421	12,300
Effect of dilutive securities:	'	'	'	'
Stock options and restricted stock units	244	315	258	284
Weighted-average number of common shares outstanding-diluted	12,647	12,620	12,679	12,584
Basic net income per share	$0.63	$0.42	$1.88	$1.58
Diluted net income per share	$0.62	$0.41	$1.84	$1.54

Net_Income_Per_Common_Share_Ad

Net Income Per Common Share - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive shares excluded from computation of diluted earnings per share	123,000	107,000	109,000	102,000

Provision_for_Benefits_from_In

Provision for (Benefits from) Income Taxes and Effective Tax Rate (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Provision For Income Taxes [Line Items]	'	'	'	'
Provision for (benefit from) income taxes	$2,509	$1,678	($6,089)	$7,418
Effective tax rate	24.00%	24.00%	-35.00%	28.00%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2013
Income Taxes [Line Items]	'	'	'
Statutory income tax rate	35.00%	'	'
Discrete tax benefit	$0	$10.60	'
Discrete tax items, favorable changes in reserves for uncertain tax positions resulting from accretion of interest, expiration of the statute of limitations and other items	0.2	'	'
Discrete tax items, unfavorable adjustment to a deferred item related to equity compensation	0.6	'	'
Reduction of taxes from change in branch accounting for Canadian operations	'	8.8	'
Remeasurement of tax reserves on a reduction in uncertain federal tax credits for R&D	'	0.9	'
Other items	'	0.9	'
Discrete tax items, miscellaneous favorables	0.4	'	'
Unrecognized tax benefit	3	3	'
Unrecognized tax benefits, accrued interest and penalties	$0.60	$0.60	$0.70

Gross_Unrecognized_Tax_Benefit

Gross Unrecognized Tax Benefits (Detail) (USD $)	Apr. 30, 2014	Jul. 31, 2013
In Millions, unless otherwise specified	Apr. 30, 2014	Jul. 31, 2013
Schedule of Unrecognized Tax Benefits [Line Items]	'	'
Gross unrecognized tax benefits	$6.60	$7.30

Segment_Information_Additional

Segment Information - Additional Information (Detail)	9 Months Ended
	Apr. 30, 2014
	Segment
Number of Segments	3

Reportable_Segment_Information

Reportable Segment Information (Detail) (USD $)	3 Months Ended			9 Months Ended
Reportable Segment Information (Detail) (USD $)	Apr. 30, 2014		Apr. 30, 2013	Apr. 30, 2014		Apr. 30, 2013	Jul. 31, 2013
Product revenue:	'		'	'		'	'
Product revenue	$122,067,000		$121,188,000	$369,992,000		$366,498,000	'
Engineering revenue:	'		'	'		'	'
Engineering revenue	1,965,000		4,577,000	5,559,000		17,688,000	'
Net revenue:	'		'	'		'	'
Total net revenue	124,032,000		125,765,000	375,551,000		384,186,000	'
Income from operations:	'		'	'		'	'
Income (loss) from continuing operations	9,417,000		6,712,000	17,136,000		27,950,000	'
Total other income (expenses), net	900,000		200,000	100,000		-1,100,000	'
Income before income taxes	10,299,000		6,902,000	17,240,000		26,832,000	'
Identifiable assets	'		'	'		'	'
Assets	602,442,000		'	602,442,000		'	587,784,000
Goodwill by segment:	'		'	'		'	'
Goodwill	56,955,000		'	56,955,000		'	50,073,000
Reportable segment assets	'		'	'		'	'
Identifiable assets	'		'	'		'	'
Assets	470,400,000		'	470,400,000		'	488,900,000
Corporate assets	'		'	'		'	'
Identifiable assets	'		'	'		'	'
Assets	132,000,000	[1]	'	132,000,000	[1]	'	98,900,000	[1]
Goodwill by segment:	'		'	'		'	'
Goodwill	6,900,000	[2]	'	6,900,000	[2]	'	'
Medical Imaging	'		'	'		'	'
Product revenue:	'		'	'		'	'
Product revenue	70,700,000		68,800,000	208,300,000		218,500,000	'
Engineering revenue:	'		'	'		'	'
Engineering revenue	1,000,000		2,900,000	3,200,000		9,900,000	'
Net revenue:	'		'	'		'	'
Total net revenue	71,700,000		71,700,000	211,500,000		228,400,000	'
Income from operations:	'		'	'		'	'
Income (loss) from continuing operations	8,900,000		6,500,000	19,300,000		22,400,000	'
Medical Imaging \| Reportable segment assets	'		'	'		'	'
Identifiable assets	'		'	'		'	'
Assets	215,800,000		'	215,800,000		'	217,100,000
Goodwill by segment:	'		'	'		'	'
Goodwill	1,900,000		'	1,900,000		'	1,900,000
Ultrasound	'		'	'		'	'
Product revenue:	'		'	'		'	'
Product revenue	37,300,000		33,900,000	112,100,000		106,000,000	'
Engineering revenue:	'		'	'		'	'
Engineering revenue	'		100,000	'		100,000	'
Net revenue:	'		'	'		'	'
Total net revenue	37,300,000		34,000,000	112,100,000		106,100,000	'
Income from operations:	'		'	'		'	'
Income (loss) from continuing operations	-1,300,000		-4,400,000	-6,100,000		-1,700,000	'
Ultrasound \| Reportable segment assets	'		'	'		'	'
Identifiable assets	'		'	'		'	'
Assets	221,700,000		'	221,700,000		'	218,400,000
Goodwill by segment:	'		'	'		'	'
Goodwill	48,200,000		'	48,200,000		'	48,200,000
Security Technology	'		'	'		'	'
Product revenue:	'		'	'		'	'
Product revenue	14,100,000		18,500,000	49,600,000		42,000,000	'
Engineering revenue:	'		'	'		'	'
Engineering revenue	1,000,000		1,600,000	2,400,000		7,700,000	'
Net revenue:	'		'	'		'	'
Total net revenue	15,100,000		20,100,000	52,000,000		49,700,000	'
Income from operations:	'		'	'		'	'
Income (loss) from continuing operations	1,800,000		4,600,000	3,900,000		7,200,000	'
Security Technology \| Reportable segment assets	'		'	'		'	'
Identifiable assets	'		'	'		'	'
Assets	$32,900,000		'	$32,900,000		'	$53,400,000

[1]	Includes cash and cash equivalents of $73.5 million and $57.4 million as of April 30, 2014 and July 31, 2013, respectively.
[2]	Includes goodwill related to the acquisition of PocketSonics. Please see Note 7. Goodwill and Other Intangible Assets for further discussion on PocketSonics.

Reportable_Segment_Information1

Reportable Segment Information (Parenthetical) (Detail) (USD $)	Apr. 30, 2014	Jul. 31, 2013	Apr. 30, 2013	Jul. 31, 2012
In Thousands, unless otherwise specified	Apr. 30, 2014	Jul. 31, 2013	Apr. 30, 2013	Jul. 31, 2012
Segment Reporting Information [Line Items]	'	'	'	'
Cash and cash equivalents	$119,448	$113,033	$91,347	$187,011
Corporate assets	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Cash and cash equivalents	$73,500	$57,400	'	'

Other_Income_Expenses_Net_Addi

Other Income (Expenses) , Net - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	Oct. 31, 2013	Apr. 30, 2014
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	PocketSonics	PocketSonics
Component Of Other Expense Income Nonoperating [Line Items]	'	'	'	'	'	'
Loss from pre-acquisition equity interest	'	'	'	'	$0.50	$0.50
Foreign exchange (gains) losses	($0.40)	($0.20)	$0.10	$1.30	'	'

Guarantees_Commitments_and_Con2

Guarantees, Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Oct. 11, 2011	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013	Jul. 31, 2013
Commitments and Contingencies Disclosure [Line Items]	'	'	'	'	'	'
Liabilities related to agreements	'	$0	'	$0	'	'
Revolving credit agreement period	'5 years	'	'	'	'	'
Borrowing outstanding under credit facilities	'	0	'	0	'	0
Business exit cost	'	0.4	0.3	1.3	0.7	'
Minimum	'	'	'	'	'	'
Commitments and Contingencies Disclosure [Line Items]	'	'	'	'	'	'
Standard product warranty term	'	'	'	'12 months	'	'
Maximum	'	'	'	'	'	'
Commitments and Contingencies Disclosure [Line Items]	'	'	'	'	'	'
Standard product warranty term	'	'	'	'36 months	'	'
Product Extended Warranty Contracts	'	'	'	'	'	'
Commitments and Contingencies Disclosure [Line Items]	'	'	'	'	'	'
Deferred revenue for product extended warranty contracts	'	9.2	'	9.2	'	8
Credit Agreement	'	'	'	'	'	'
Commitments and Contingencies Disclosure [Line Items]	'	'	'	'	'	'
Credit facility maximum borrow capacity	100	'	'	'	'	'
Credit facility, expiry date	10-Oct-16	'	'	'	'	'
Percentage of capital stock pledge as collateral	65.00%	'	'	'	'	'
Leverage ratio	'	0.01%	'	0.01%	'	'
Credit facility transaction costs incurred	'	0.5	'	0.5	'	'
Credit facility, maturity period	'	'	'	'5 years	'	'
Credit Agreement \| Other Revolving Credit Facilities	'	'	'	'	'	'
Commitments and Contingencies Disclosure [Line Items]	'	'	'	'	'	'
Credit facility available borrowing capacity	'	4.2	'	4.2	'	'
Credit Agreement \| Minimum	'	'	'	'	'	'
Commitments and Contingencies Disclosure [Line Items]	'	'	'	'	'	'
Credit facility commitment fee percentage	0.20%	'	'	'	'	'
Interest coverage ratio	'	300.00%	'	300.00%	'	'
Credit Agreement \| Maximum	'	'	'	'	'	'
Commitments and Contingencies Disclosure [Line Items]	'	'	'	'	'	'
Aggregate available credit amount under specified circumstances	150	'	'	'	'	'
Credit facility commitment fee percentage	0.35%	'	'	'	'	'
Leverage ratio of total debt to earnings before interest, taxes, depreciation, and amortization or EBITDA	'	'	'	275.00%	'	'
Credit Agreement \| Libor Rate \| Minimum	'	'	'	'	'	'
Commitments and Contingencies Disclosure [Line Items]	'	'	'	'	'	'
Variable interest rate	1.25%	'	'	'	'	'
Credit Agreement \| Libor Rate \| Maximum	'	'	'	'	'	'
Commitments and Contingencies Disclosure [Line Items]	'	'	'	'	'	'
Variable interest rate	2.00%	'	'	'	'	'
Credit Agreement \| Defined Base Rate \| Minimum	'	'	'	'	'	'
Commitments and Contingencies Disclosure [Line Items]	'	'	'	'	'	'
Variable interest rate	0.00%	'	'	'	'	'
Credit Agreement \| Defined Base Rate \| Maximum	'	'	'	'	'	'
Commitments and Contingencies Disclosure [Line Items]	'	'	'	'	'	'
Variable interest rate	1.00%	'	'	'	'	'

Product_Warranty_Liability_Det

Product Warranty Liability (Detail) (USD $)	9 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2014	Jul. 31, 2013
Product Liability Contingency [Line Items]	'	'
Product warranty liability, beginning balance	$6.50	$5.60
Provision	3.1	5.3
Ultrasonix warranty accrual acquired	'	1.2
Settlements made in cash or in kind during the period	-3.4	-5.6
Product warranty liability, ending balance	$6.20	$6.50

Leases_and_Other_Commitments_A

Leases and Other Commitments - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Lease and Rental Expense [Line Items]	'	'	'	'
Rent expense associated with the Company's operating leases	$0.40	$0.50	$1.60	$1.20
Outstanding non-cancelable purchase orders	$55.70	'	$55.70	'

Future_Minimum_Lease_Payments_

Future Minimum Lease Payments (Detail) (USD $)	Apr. 30, 2014
In Millions, unless otherwise specified	Apr. 30, 2014
Schedule of Operating Leases [Line Items]	'
2014 (3 months)	$0.80
2015	2.1
2016	1.3
2017	0.9
2018	0.7
Thereafter	1.2
Operating Leases, Future Minimum Payments Due, Total	$7

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (Subsequent Event, USD $)	1 Months Ended
In Millions, except Per Share data, unless otherwise specified	Jun. 03, 2014
Maximum	'
Subsequent Event [Line Items]	'
Amount authorized an additional repurchase of Company's common stock	$30
Dividend Declared	'
Subsequent Event [Line Items]	'
Dividend declaration date	3-Jun-14
Dividend declared	$0.10
Dividend payable date	26-Jun-14
Dividend record date	16-Jun-14